0001493152-16-013281.txt : 20160913 0001493152-16-013281.hdr.sgml : 20160913 20160913103133 ACCESSION NUMBER: 0001493152-16-013281 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 40 CONFORMED PERIOD OF REPORT: 20160731 FILED AS OF DATE: 20160913 DATE AS OF CHANGE: 20160913 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SCIVANTA MEDICAL CORP CENTRAL INDEX KEY: 0001093285 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 222436721 STATE OF INCORPORATION: DE FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-27119 FILM NUMBER: 161882171 BUSINESS ADDRESS: STREET 1: 215 MORRIS AVENUE CITY: SPRING LAKE STATE: NJ ZIP: 07762 BUSINESS PHONE: (732) 919-2799 MAIL ADDRESS: STREET 1: 215 MORRIS AVENUE CITY: SPRING LAKE STATE: NJ ZIP: 07762 FORMER COMPANY: FORMER CONFORMED NAME: MEDI HUT CO INC DATE OF NAME CHANGE: 19990816 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

[X]	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the quarterly period ended July 31, 2016

[ ]	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from _________ to _________

Commission file number 0-27119

SCIVANTA MEDICAL CORPORATION

(Exact name of registrant as specified in its charter)

Nevada		22-2436721
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

215 Morris Avenue, Spring Lake, New Jersey 07762

(Address of principal executive offices)

(732) 282-1620

(Issuer’s telephone number)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and smaller reporting company in Rule 12b-2 of the Securities Exchange Act of 1934.

Large accelerated filer	[ ]		Accelerated filer	[ ]
Non-accelerated filer	[ ]	(Do not check if a smaller reporting company)	Smaller reporting company	[X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes [X] No [ ]

As of September 9, 2016, there were 20,934,717 shares of the registrant’s common stock, par value $.001 per share, outstanding.

SCIVANTA MEDICAL CORPORATION

INDEX TO FORM 10-Q

		Page
PART I	FINANCIAL INFORMATION

Item 1.	Financial Statements	1

	Balance Sheets (unaudited) as of July 31, 2016 and October 31, 2015	2

	Statements of Operations (unaudited) for the three and nine months ended July 31, 2016 and 2015	3

	Statements of Cash Flows (unaudited) for the nine months ended July 31, 2016 and 2015	4

	Notes to the Unaudited Financial Statements	5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	17

Item 4.	Controls and Procedures	17

PART II	OTHER INFORMATION

Item 1.	Legal Proceedings	18

Item 1A.	Risk Factors	18

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18

Item 3.	Defaults Upon Senior Securities	18

Item 4.	Mine Safety Disclosures	18

Item 5.	Other Information	18

Item 6.	Exhibits	18

Signatures		19

Index of Exhibits		E-1

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain information included in this quarterly report on Form 10-Q and other filings of the registrant under the Securities Act of 1933, as amended (the “Securities Act”), and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as well as information communicated orally or in writing between the dates of such filings, contains or may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing.

Forward-looking statements may include the words “may”, “could”, “estimate”, “intend”, “continue”, “believe”, “expect” or “anticipate” or other similar words. These forward-looking statements present our estimates and assumptions only as of the date of this quarterly report on Form 10-Q. Except as may be required under applicable securities laws, we do not intend, and undertake no obligation, to update any forward-looking statement. You should, however, consult further disclosures we make in future filings of our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Additionally, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 most likely do not apply to our forward-looking statements because we are considered a penny stock issuer.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

The balance sheet as of July 31, 2016 and the related statements of operations for the three and nine months ended July 31, 2016 and 2015 and cash flows for the nine months ended July 31, 2016 and 2015 for Scivanta Medical Corporation (“Scivanta” or the “Company”) included in Item 1, have been prepared by us, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures required under accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted from the following financial statements pursuant to the rules and regulations of the SEC. In the opinion of management, the accompanying financial statements include all adjustments, which are of a normal and recurring nature, necessary to present fairly our financial position and results of operations. It is suggested that the following financial statements be read in conjunction with the financial statements and notes thereto included in the registrant’s annual report on Form 10-K for the fiscal year ended October 31, 2015.

The results of operations for the three and nine months ended July 31, 2016 are not necessarily indicative of the results of the entire fiscal year or for any other period.

Scivanta Medical Corporation

Balance Sheets

(Unaudited)

	July 31, 2016			October 31, 2015
Assets
Current assets:
Cash	$	28,148		$	21,658
Prepaid expenses		4,739			6,969

Total current assets and total assets	$	32,887		$	28,627

Liabilities and Stockholders’ Deficiency
Current liabilities:
Accounts payable	$	125,880		$	102,086
Accounts payable - related party		44,149			369,479
Accrued expenses		34,937			119,046
Convertible debentures		225,000			694,791

Total current liabilities		429,966			1,285,402

Note payable		—			105,000

Total liabilities		429,966			1,390,402

Commitments

Stockholders’ deficiency:
Preferred stock, $.001 par value; 20,000,000 shares authorized; no shares issued		—			—
Common stock, $.001 par value; 500,000,000 shares authorized; 20,934,717 and 6,359,055 shares issued and outstanding, respectively		20,935			6,359
Additional paid-in capital		24,231,579			23,080,594
Accumulated deficit		(24,649,593	)		(24,448,728	)

Total stockholders’ deficiency		(397,079	)		(1,361,775	)

Total liabilities and stockholders’ deficiency	$	32,887		$	28,627

The accompanying notes are an integral part of these financial statements.

Scivanta Medical Corporation

Statements of Operations

(Unaudited)

	Three Months Ended July 31,						Nine Months Ended July 31,
	2016			2015			2016			2015

Revenue	$	—		$	—		$	—		$	—

Operating expenses:
General and administrative		64,843			62,829			215,968			176,979
Gain on settlement of note payable		—			—			(105,000	)		—

Loss from operations		(64,843	)		(62,829	)		(110,968	)		(176,979	)

Interest expense		(4,536	)		(16,916	)		(41,640	)		(54,342	)
Loss on inducement of convertible debentures		—			—			(48,257	)		—

Net loss	$	(69,379	)	$	(79,745	)	$	(200,865	)	$	(231,321	)

Net loss per common share, basic and diluted	$	0.00		$	(0.01	)	$	(0.02	)	$	(0.04	)

Weighted average number of common shares outstanding, basic and diluted		20,861,786			6,359,055			12,093,663			6,359,055

The accompanying notes are an integral part of these financial statements.

Scivanta Medical Corporation

Statements of Cash Flows

(Unaudited)

	Nine Months Ended July 31,
	2016			2015
Cash flows from operating activities:
Net loss	$	(200,865	)	$	(231,321	)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on settlement of note payable		(105,000	)		—
Accretion of interest on convertible debentures		8,713			11,261
Loss on inducement of convertible debentures		48,257			—
Changes in operating assets and liabilities:
Prepaid expenses		2,230			3,783
Accounts payable		23,794			(1,719	)
Accounts payable - related party		131,434			116,830
Accrued expenses		47,927			38,582
Net cash used in operating activities		(43,510	)		(62,584	)
Cash flows from financing activities:
Proceeds from issuance of convertible debenture		50,000			50,000
Increase (decrease) in cash		6,490			(12,584	)
Cash - beginning of period		21,658			26,114
Cash – end of period	$	28,148		$	13,530
Supplemental disclosure of cash flow information:
Cash paid for income taxes	$	500		$	500
Noncash financing activities:
Discount recorded in connection with issuance of convertible debenture	$	3,504		$	7,610
Issuance of 7,548,522 shares of common stock as payment of principal and interest due on convertible debentures	$	657,036		$	—
Issuance of 7,027,140 shares of common stock as settlement of accounts payable – related party	$	456,764		$	—

The accompanying notes are an integral part of these financial statements.

Scivanta Medical Corporation

Notes to the Unaudited Financial Statements

Basis of Presentation

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant recurring operating losses and negative cash flows from operations. The Company had a working capital deficiency of $397,079 and an accumulated deficit of $24,649,593 as of July 31, 2016. The Company has not made the $25,000 principal payment due on a convertible debenture and, as a result, that obligation can be placed in default by the holder. The Company also has no lending relationships with commercial banks and is dependent on the completion of a financing involving the private placement of its securities in order to continue operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

On November 10, 2006, the Company licensed the exclusive world-wide rights to develop, manufacture and distribute certain proprietary technologies known as the Scivanta Cardiac Monitoring System (the “SCMS”), a minimally invasive two-balloon esophageal catheter system used to monitor cardiac performance. On January 22, 2016, the Company and the Licensor (as hereinafter defined) terminated the SCMS license agreement and, as a result, all property related to the SCMS held by the Company, including intellectual property, was assigned and returned to the Licensor (see Note 2).

The Company’s strategy for business development is focused on the acquisition, through licensing or purchasing, of medical devices, pharmaceuticals and other proprietary technologies, patented products or services. Any such acquisitions will be contingent upon the Company’s ability to secure the financing required to fund such acquisitions.

The Company continues to seek equity and/or debt investors and from time to time engages placement agents to assist the Company in this initiative. Effective November 1, 2011, each of the Company’s officers agreed to waive the annual base salary due to them and each of the Company’s directors agreed to waive the annual retainer and meeting fees due to them until the Company is able to raise sufficient capital that would provide the Company with the ability to pay cash compensation to its officers and directors. The Company has also paid certain obligations with shares of its common stock and has deferred certain other vendor payments until the Company secures sufficient additional debt or equity financing.

While the Company is pursuing the opportunities and actions described above, there can be no assurance that it will be successful in its efforts. If the Company is unable to secure additional capital, it will explore other strategic alternatives, including, but not limited to, the sale of the Company. Any additional equity financing may result in substantial dilution to our stockholders.

Amended and Restated SCMS License Agreement

On February 14, 2011, the Company entered into an Amended and Restated Technology License Agreement with The Research Foundation of State University of New York, for and on behalf of the University at Buffalo (the “Foundation”), Donald D. Hickey, M.D. (“Hickey”) and Clas E. Lundgren (“Lundgren”). The Foundation, Hickey and Lundgren shall be collectively referred to herein as the “Licensor”. The Amended and Restated Technology License Agreement, as further amended on March 14, 2013, is referred to herein as the “License Agreement”.

Pursuant to the License Agreement, the Licensor granted the Company the exclusive world-wide rights to develop, manufacture and distribute certain proprietary technologies known as the SCMS. A cash payment of $105,000 was payable by the Company to Hickey as follows: (a) $50,000 was due to Hickey on or before a date that is thirty (30) days after the closing of any single financing by the Company of at least $3,000,000 or any series of financings by the Company within a six (6) month period totaling at least $3,000,000; and (b) $55,000 was due to Hickey on or before the date that is thirty (30) days after the first commercial sale of a product utilizing the licensed technology (see Note 4).

On January 22, 2016, the Company and the Licensor entered into an agreement to terminate the License Agreement (the “License Termination Agreement”). The Company and the Licensor released each other from any and all claims and liabilities related to the License Agreement, including the $105,000 payment due to Hickey (see Note 4). In addition, pursuant to the License Termination Agreement, the Company assigned all intellectual property related to the SCMS to the Licensor and returned all property in its possession related to the SCMS to the Licensor.

Related Party Transactions

David R. LaVance, the Company’s Chairman, President and Chief Executive Officer, and Thomas S. Gifford, the Company’s Executive Vice President, Chief Financial Officer and Secretary, are principals of Century Capital Associates LLC (“Century Capital”). Effective February 1, 2007, the Company and Century Capital entered into a sublease agreement (the “Sublease Agreement”) pursuant to which the Company rents office space approximating 2,000 square feet inside Century Capital’s existing offices. In addition, the Company rents office furniture and other equipment from Century Capital. This agreement has a month to month term that requires sixty days written notice to terminate and a monthly rental fee of $5,000. The Company is responsible for all operating costs associated with the office space, including utilities, maintenance and property taxes.

During the three and nine months ended July 31, 2016, the Company was billed $20,229 and $58,464, respectively, pursuant to the terms of the Sublease Agreement. On April 30, 2016, the Company paid $135,000 of rent and $36,899 of expenses due under the Sublease Agreement for the period commencing February 1, 2014 through April 30, 2016 and $284,865 of other expenses due to Century Capital for the period commencing September 1, 2013 through April 30, 2016 through the issuance of 7,027,140 shares of the Company’s common stock. As of July 31, 2016, the Company owed Century Capital $15,000 for rent due under the Sublease Agreement, $5,229 for expenses due under the Sublease Agreement and $23,920 for other expenses, which amounts are presented in accounts payable – related party. During the three and nine months ended July 31, 2015, the Company was billed $19,057 and $53,750, respectively, pursuant to the terms of the Sublease Agreement.

Note Payable

Pursuant to the License Agreement, a cash payment of $105,000 was payable to Hickey. Pursuant to the License Termination Agreement, the Licensor released the Company from any obligation regarding payment of the $105,000 to Hickey (see Note 2). Accordingly, for the nine months ended July 31, 2016, the Company recorded a $105,000 gain on the settlement of the note payable.

Convertible Debentures

February 2007 Convertible Debentures

On February 8, 2007, the Company issued 8% convertible debentures, dated February 1, 2007, in the aggregate principal amount of $250,000 to individual investors (the “February 2007 Debentures”). The February 2007 Debentures bear interest at a rate of 8% per annum and originally had a three year term, maturing on January 31, 2010, which was initially extended to January 31, 2012.

On January 11, 2012, the Company issued 50,000 shares of common stock as full payment of $50,000 of outstanding principal on certain February 2007 Debentures. On March 31, 2016, the Company issued 856,934 shares of common stock as full payment of $175,000 of outstanding principal due on the February 2007 Debentures and $34,302 of accrued and unpaid interest for the period commencing February 1, 2014 through March 31, 2016 (January 31, 2016 for the February 2007 Debenture that was not converted into shares of common stock on March 31, 2016). The number of shares issued as payment of the principal due was based on the conversion price as defined in the February 2007 Debentures and the number of shares issued as payment of the interest due was calculated based on the market price of the Company’s common stock as defined in the February 2007 Debentures.

As of July 31, 2016, the remaining outstanding principal amount of the February 2007 Debentures was $25,000. The Company has not made payment on the outstanding balance of the remaining February 2007 Debenture and, as a result, such obligation can be placed in default by the holder.

For the three and nine months ended July 31, 2016, the Company recorded a total of $504 and $7,330, respectively, of interest expense related to the February 2007 Debentures. For the three and nine months ended July 31, 2015, the Company recorded a total of $4,033 and $11,968, respectively, of interest expense related to the February 2007 Debentures. As of July 31, 2016, $997 of interest due on the February 2007 Debentures was accrued and is included as a component of accrued expenses. As of July 31, 2016, the Company recorded the $25,000 of outstanding principal due on the remaining February 2007 Debenture as a component of current convertible debentures.

May 2011 Convertible Debenture

On May 20, 2011, the Company issued an 8% convertible debenture in the principal amount of $100,000 to an institutional investor (the “May 2011 Debenture”). The May 2011 Debenture bears interest at a rate of 8% per annum and originally had a three year term maturing on May 20, 2014 that was initially extended to May 20, 2015. Effective April 1, 2016, the holder agreed to a new maturity date of March 31, 2017.

On March 31, 2016, the Company issued 128,205 shares of common stock to the May 2011 Debenture holder in satisfaction of $16,000 of interest due for the period commencing May 20, 2013 through May 19, 2015. On June 22, 2016, the Company issued 129,032 shares of common stock to the May 2011 Debenture holder in satisfaction of $8,000 of interest due for the period commencing May 20, 2015 through May 19, 2016. The number of shares issued as payment of the interest due was calculated based on the market price of the Company’s common stock as defined in the May 2011 Debenture.

For the three and nine months ended July 31, 2016, the Company recorded a total of $2,016 and $6,006 of interest expense related to the May 2011 Debenture. For the three and nine months ended July 31, 2015, the Company recorded a total of $2,017 and $5,985 of interest expense related to the May 2011 Debenture. As of July 31, 2016, $1,630 of interest due on the May 2011 Debenture was accrued and is included as a component of accrued expenses. As of July 31, 2016, the Company recorded the $100,000 of outstanding principal due on the May 2011 Debenture as a component of current convertible debentures.

August 2012 Convertible Debenture

On August 15, 2012, the Company issued an 8% convertible debenture in the principal amount of $100,000 to an institutional investor (the “August 2012 Debenture”). The August 2012 Debenture originally had a three year term maturing on August 15, 2015 and bears interest at a rate of 8% per annum. Effective April 1, 2016, the holder agreed to a new maturity date of March 31, 2017.

On March 31, 2016, the Company issued 161,538 shares of common stock to the August 2012 Debenture holder in satisfaction of $16,000 of interest due for the period commencing August 15, 2013 through August 14, 2015. The number of shares issued as payment of the interest due was calculated based on the market price of the Company’s common stock as defined in the August 2012 Debenture.

For the three and nine months ended July 31, 2016, the Company recorded a total of $2,016 and $6,006 of interest expense related to the August 2012 Debenture. For the three and nine months ended July 31, 2015, the Company recorded a total of $2,017 and $5,985 of interest expense related to the August 2012 Debenture. As of July 31, 2016, $7,810 of interest due on the August 2012 Debenture was accrued and is included as a component of accrued expenses. As of July 31, 2016, the Company recorded the $100,000 of outstanding principal due on the August 2012 Debenture as a component of current convertible debentures.

December 2013 and April 2014 Convertible Debentures and Warrants

On December 12, 2013, the Company issued 10% convertible debentures in the aggregate principal amount of $150,000 to two individual investors (the “December 2013 Debentures”) and on April 1, 2014, the Company issued a 10% convertible debenture in the principal amount of $75,000 to one individual investor (the “April 2014 Debenture” and together with the December 2013 Debentures, the “Debentures”). In connection with the issuance of the Debentures, the Company issued warrants (the “Debenture Warrants”) to purchase shares of the Company’s common stock equal to 20% of the aggregate principal amount of the Debentures. The Debentures had a one year term with principal and interest on the December 2013 Debentures due December 12, 2014 and principal and interest on the April 2014 Debenture due April 1, 2015. The Debentures bear interest at a rate of 10% per annum.

The Company separately accounted for the liability and equity components of the Debentures based upon the relative fair value of the liability and equity components on the date of issuance. As a result, the Company recorded a discount of $36,796 for the Debentures to account for the relative fair value attributable to the Debenture Warrants. The $36,796 debt discount was accreted as interest expense using the effective interest method over the respective one-year terms of the Debentures.

On March 31, 2016, the Company issued 4,223,392 shares of common stock, at $0.065 per share, as full payment of the $225,000 of outstanding principal and $49,521 of accrued and unpaid interest due on the Debentures. Due to the reduction in the conversion price from $0.13 per share (as provided in the Debentures) to $0.065 per share, the Company recorded a loss on the inducement of the Debentures of $40,122 during the nine months ended July 31, 2016.

For the three and nine months ended July 31, 2016, the Company recorded a total of $0 and $9,269, respectively, of interest expense related to the Debentures. For the three and nine months ended July 31, 2015, the Company recorded a total of $5,671 and $24,566 ($7,738 accreted), respectively, of interest expense related to the Debentures.

February 2015 Convertible Debenture and Warrant

On February 12, 2015, the Company issued a 10% convertible debenture in the principal amount of $50,000 to an individual investor (the “February 2015 Debenture”). In connection with the issuance of the February 2015 Debenture, the Company issued a warrant (the “February 2015 Debenture Warrant”) to purchase shares of its common stock equal to 20% of the aggregate principal amount of the February 2015 Debenture. The February 2015 Debenture had a one-year term with principal and interest due February 12, 2016. The February 2015 Debenture bears interest at a rate of 10% per annum.

The Company separately accounted for the liability and equity components of the February 2015 Debenture based upon the relative fair value of the liability and equity components on the date of issuance. As a result, the Company recorded a discount of $5,983 for the February 2015 Debenture to account for the relative fair value attributable to the February 2015 Debenture Warrant. The $5,983 debt discount was accreted as interest expense using the effective interest method over the one-year term of the February 2015 Debenture.

On March 31, 2016, the Company issued 856,270 shares of common stock, at $0.065 per share, as full payment of the $50,000 of outstanding principal and $5,658 of accrued and unpaid interest due on the February 2015 Debenture. Due to the reduction in the conversion price from $0.13 per share (as provided in the February 2015 Debenture) to $0.065 per share, the Company recorded a loss on the inducement of the February 2015 Debenture of $8,135 during the nine months ended July 31, 2016.

For the three and nine months ended July 31, 2016, the Company recorded a total of $0 and $3,788 ($1,705 accreted), respectively, of interest expense related to the February 2015 Debenture. For the three and nine months ended July 31, 2015, the Company recorded a total of $3,178 ($1,918 accreted) and $5,838 ($3,523 accreted), respectively, of interest expense related to the February 2015 Debenture.

September 2015 Convertible Debentures and Warrants

On September 14, 2015, the Company issued 10% convertible debentures in the aggregate principal amount of $25,000 to three individual investors (the “September 2015 Debentures”). In connection with the issuance of the September 2015 Debentures, the Company issued warrants (the “September 2015 Debenture Warrants”) to purchase shares of its common stock equal to 20% of the aggregate principal amount of the September 2015 Debentures. The September 2015 Debentures had a one-year term with principal and interest due September 14, 2016. The September 2015 Debentures bear interest at a rate of 10% per annum.

The Company separately accounted for the liability and equity components of the September 2015 Debentures based upon the relative fair value of the liability and equity components on the date of issuance. As a result, the Company recorded a discount of $4,022 for the September 2015 Debentures to account for the relative fair value attributable to the September 2015 Debenture Warrants. The $4,022 debt discount was accreted as interest expense using the effective interest method over the term of the September 2015 Debentures (September 14, 2015 through March 31, 2016, the date the September 2015 Debentures were converted into shares of common stock).

On March 31, 2016, the Company issued 405,585 shares of common stock, at $0.065 per share as provided in the September 2015 Debentures, as full payment of the $25,000 of outstanding principal and $1,363 of accrued and unpaid interest due on the September 2015 Debentures.

For the three and nine months ended July 31, 2016, the Company recorded a total of $0 and $4,545 ($3,504 accreted), respectively, of interest expense related to the September 2015 Debentures.

January 2016 Convertible Debenture and Warrant

On January 4, 2016, the Company issued a 10% convertible debenture in the principal amount of $50,000 to an individual investor (the “January 2016 Debenture”). In connection with the issuance of the January 2016 Debenture, the Company issued a warrant (the “January 2016 Debenture Warrant”) to purchase shares of its common stock equal to 20% of the aggregate principal amount of the January 2016 Debenture. The January 2016 Debenture had a one-year term with principal and interest due January 4, 2017. The January 2016 Debenture bears interest at a rate of 10% per annum.

The Company separately accounted for the liability and equity components of the January 2016 Debenture based upon the relative fair value of the liability and equity components on the date of issuance. As a result, the Company recorded a discount of $3,504 for the January 2016 Debenture to account for the relative fair value attributable to the January 2016 Debenture Warrant. The $3,504 debt discount was accreted as interest expense using the effective interest method over the term of the January 2016 Debenture (January 4, 2016 through March 31, 2016, the date the January 2016 Debenture was converted into shares of common stock).

On March 31, 2016, the Company issued 787,566 shares of common stock, at $0.065 per share as provided in the January 2016 Debenture, as full payment of the $50,000 of outstanding principal and $1,192 of accrued and unpaid interest due on the January 2016 Debenture.

For the three and nine months ended July 31, 2016, the Company recorded a total of $0 and $4,696 ($3,504 accreted), respectively, of interest expense related to the January 2016 Debenture.

Stock-Based Compensation

The Company accounts for stock-based payments to employees in accordance with Accounting Standards Codification (“ASC”) 718, “Stock Compensation” (“ASC 718”). All stock-based payments to employees are grants of stock options that are recognized in the statement of operations based on their fair values at the date of grant. For each of the three and nine months ended July 31, 2016 and 2015, the Company did not record any employee stock-based compensation expense.

The Company accounts for stock-based payments to non-employees in accordance with ASC 718 and ASC 505-50, “Equity-Based Payments to Non-Employees.” For each of the three and nine months ended July 31, 2016 and 2015, the Company did not record any non-employee stock-based compensation expense.

Net Loss Per Common Share

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not deemed to be anti-dilutive. The dilutive effect of the outstanding stock options and warrants is computed using the treasury stock method.

As of July 31, 2016, diluted net loss per share did not include the effect of 193,332 shares of common stock issuable upon the exercise of outstanding options, 903,846 shares of common stock issuable upon the exercise of outstanding warrants and 593,750 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive.

As of July 31, 2015, diluted net loss per share did not include the effect of 203,332 shares of common stock issuable upon the exercise of outstanding options, 673,077 shares of common stock issuable upon the exercise of outstanding warrants and 2,782,051 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive.

Stockholders’ Equity

Issuance of Common Stock as Payment of Interest on Convertible Debenture

Stock Option Plans

The Company currently has two stock option plans in place: the 2002 Equity Incentive Plan and the 2007 Equity Incentive Plan (collectively, the “Equity Incentive Plans”). The 2002 Equity Incentive Plan was approved by the stockholders on July 5, 2002. The aggregate number of shares of common stock which could have been awarded under the 2002 Equity Incentive Plan was 200,000. As of July 31, 2016, options to purchase 110,000 shares of the Company’s common stock were outstanding under the 2002 Equity Incentive Plan. As a result of the adoption of the Company’s 2007 Equity Incentive Plan, no further awards are permitted under the 2002 Equity Incentive Plan.

On May 31, 2007, the stockholders approved the Company’s 2007 Equity Incentive Plan. The original aggregate number of shares of common stock which could be awarded under the 2007 Equity Incentive Plan was 300,000 shares, subject to adjustment as provided in the 2007 Equity Incentive Plan. Effective December 27, 2013, as permitted under the 2007 Equity Incentive Plan, the Company’s board of directors increased the number of shares of common stock that could be awarded under the 2007 Equity Incentive Plan to 814,408 shares. As of July 31, 2016, options to purchase 83,332 shares of the Company’s common stock were outstanding under the 2007 Equity Incentive Plan and up to 731,076 shares of the Company’s common stock remain available for awards under the 2007 Equity Incentive Plan.

Stock option awards under the Equity Incentive Plans were granted at prices as determined by the Company’s compensation committee, but such prices were not less than the fair market value of the Company’s common stock on the date of grant. Stock options granted and outstanding include only non-qualified stock options that vested over a period of up to five years and have a maximum term of ten years from the date of grant.

A summary of stock option transactions for employees and directors under the Equity Incentive Plans during the nine months ended July 31, 2016 is as follows:

	Stock Option Shares			Weighted Average Exercise Price Per Common Share		Aggregate Intrinsic Value
Outstanding at October 31, 2015		203,332		$	1.70	$	—
Granted during the period		—			—
Exercised during the period		—			—
Expired during the period		(10,000	)	$	0.80
Outstanding at July 31, 2016		193,332		$	1.74	$	—
Exercisable at July 31, 2016		193,332		$	1.74	$	—
Exercisable at October 31, 2015		203,332		$	1.70	$	—

Information with respect to stock options outstanding and stock options exercisable as of July 31, 2016 that were granted to employees is as follows:

		Stock Options Outstanding						Stock Options Exercisable
Exercise Price		Number of Shares Available Under Outstanding Stock Options		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)		Number of Shares Available for Purchase Under Outstanding Stock Options		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)

$	1.40		83,332	$	1.40		2.1		83,332	$	1.40		2.1
$	2.00		110,000	$	2.00		0.5		110,000	$	2.00		0.5
			193,332	$	1.74		1.2		193,332	$	1.74		1.2

Warrant to Purchase Common Stock

A summary of warrant transactions during the nine months ended July 31, 2016 is as follows:

	Warrant Shares		Weighted Average Exercise Price Per Common Share		Aggregate Intrinsic Value

Outstanding at October 31, 2015		750,000	$	0.12	$	—
Issued during the period		153,846	$	0.07
Exercised during the period		—		—
Expired during the period		—		—
Outstanding at July 31, 2016		903,846	$	0.11	$	—
Exercisable at July 31, 2016		673,077	$	0.13	$	—
Exercisable at October 31, 2015		596,154	$	0.13	$	—

As of July 31, 2016, the weighted average remaining contractual life for warrants outstanding was 1.6 years and for warrants exercisable was 1.3 years.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Background

Scivanta is a Nevada corporation headquartered in Spring Lake, New Jersey. Scivanta currently does not sell any products or technologies.

On November 10, 2006, we acquired the exclusive world-wide rights to develop, manufacture and distribute the SCMS, a minimally invasive two-balloon esophageal catheter system used to monitor cardiac performance. On January 22, 2016, Scivanta and the Licensor entered into the License Termination Agreement pursuant to which the License Agreement was terminated and, as a result, all property related to the SCMS held by Scivanta, including intellectual property, was assigned and returned to the Licensor. Scivanta is currently searching for a new business, technology, product or service to acquire.

Scivanta is currently operating on a limited basis as it continues to seek additional financing that will allow it to acquire a new technology, product or service. Our business development strategy will depend upon our ability to secure additional financing.

In the event that we acquire a new technology, product or service, no assurances can be given that we will have the financial and other resources necessary for us to acquire additional technologies, products or services. In addition, no assurances can be given that any technology, product or service that we acquire as part of our business development strategy will be profitable.

Critical Accounting Policies and Estimates

The discussion and analysis of the Company’s financial condition and results of operations are based upon the interim financial statements contained elsewhere herein, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements required us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to income taxes, contingencies and litigation. We based our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

The critical accounting estimates that we believe affect the more significant judgments and estimates used in preparation of the financial statements contained elsewhere herein are described in the Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to the Financial Statements included in the Company’s annual report on Form 10-K for the fiscal year ended October 31, 2015. There have been no material changes to the critical accounting policies.

Results of Operations

General and Administrative. For the three months ended July 31, 2016, general and administrative expenses were $64,843, as compared to $62,829 for the three months ended July 31, 2015. The $2,014, or 3%, increase in general and administrative expenses for the three months ended July 31, 2016 was primarily due to a $2,020 increase in legal expenses related to fundraising efforts and evaluation of potential acquisitions, a $1,333 increase in office related expenses and a $1,266 increase in expenses related to SEC filings and common stock issuances, offset by a $3,925 decrease in travel related expenses.

For the nine months ended July 31, 2016, general and administrative expenses were $215,968, as compared to $176,979 for the nine months ended July 31, 2015. The $38,989, or 22%, increase in general and administrative expenses for the nine months ended July 31, 2016 was primarily due to an $18,000 increase in consulting expenses and a $12,654 increase in legal expenses, each related to fundraising efforts and evaluation of potential acquisitions, and a $5,186 increase in office related expenses.

The amount of general and administrative expense to be incurred by us during the fiscal year ending October 31, 2016 will depend upon our ability to secure additional capital through an equity and/or debt financing or corporate partnerships. In the event that we are able to obtain additional capital sufficient to fund the acquisition of a new business, product, technology or service, we would expect general and administrative expenses for the fiscal year ending October 31, 2016 to increase as we build the administrative infrastructure necessary to support the development or sale of a new business, product, technology or service. If we are unable to obtain additional capital sufficient to fund the acquisition of a new business, product, technology or service, we would expect general and administrative expenses for the fiscal year ending October 31, 2016 to remain at current minimum levels.

Gain on Settlement of Note Payable. For the nine months ended July 31, 2016, we recognized a $105,000 gain on the settlement of the note payable to Hickey pursuant to the License Termination Agreement.

Interest Expense. For the three months ended July 31, 2016, interest expense was $4,536, as compared to $16,916 for the three months ended July 31, 2015. The $12,380, or 73%, decrease in interest expense for the three months ended July 31, 2016 was primarily due to the April 30, 2016 conversion of outstanding principal on the February 2007 Debentures, the December 2013 Debentures, the April 2014 Debenture and the February 2015 Debenture into shares of common stock.

For the nine months ended July 31, 2016, interest expense was $41,640, as compared to $54,342 for the nine months ended July 31, 2015. The $12,702, or 23%, decrease in interest expense for the nine months ended July 31, 2016 was primarily due to the April 30, 2016 conversion of outstanding principal on the February 2007 Debentures, the December 2013 Debentures, the April 2014 Debenture and the February 2015 Debenture into shares of common stock.

Loss on Inducement of Convertible Debentures. For the nine months ended July 31, 2016, we recognized a loss of $48,257 on the conversion of certain convertible debentures due to a reduction in the conversion price.

Net Loss. For the three months ended July 31, 2016, our net loss was $69,379, or $0.00 per share (basic and diluted), as compared to a net loss of $79,745, or $0.01 per share (basic and diluted), for the three months ended July 31, 2015. The $10,366, or 13%, decrease in net loss for the three months ended July 31, 2016 was due to a $12,380 decrease in interest expense, offset by a $2,014 increase in general and administrative expenses.

For the nine months ended July 31, 2016, our net loss was $200,865, or $0.02 per share (basic and diluted), as compared to a net loss of $231,321, or $0.04 per share (basic and diluted), for the nine months ended July 31, 2015. The $30,456, or 13%, decrease in net loss for the nine months ended July 31, 2016 was due a $105,000 gain on the settlement of a note payable and a $12,702 decrease in interest expense, offset by a $38,989 increase in general and administrative expenses and a $48,257 loss on the inducement of convertible debentures.

Liquidity and Capital Resources

As of July 31, 2016, we had a working capital deficiency of $397,079 and cash on hand of $28,148. The $6,490 increase in cash on hand from October 31, 2015 was primarily due to the receipt of $50,000 of gross proceeds from the January 2016 Debenture, offset by our continuing operating expenses.

During the past several years, we generally sustained recurring losses and negative cash flows from operations. We currently do not generate any revenue from operations. Our operations most recently have been funded through a combination of the sale of our convertible debentures and common stock and through the issuance of our common stock in exchange for services.

On March 31, 2016, we issued 7,419,490 shares of our common stock as payment of $649,036 of outstanding principal and accrued interest on certain convertible debentures. On April 30, 2016, we issued 7,027,140 shares of our common stock as payment of $456,764 related party accounts payable. On June 22, 2016, we issued 129,032 shares of our common stock as payment of $8,000 of interest due on a convertible debenture.

As of September 9, 2016, our cash position was approximately $22,400. Without any additional financing, we will only be able to continue our administrative operations, on a limited basis, for approximately four months from the filing date of this quarterly report on Form 10-Q. Effective November 1, 2011, Scivanta’s officers agreed to waive the annual base salary due to them and Scivanta’s directors agreed to waive the annual retainer and meeting fees due to them until Scivanta is able to raise sufficient capital that would provide Scivanta with the ability to pay cash compensation to its officers and directors. Scivanta has also deferred certain vendor payments until it secures sufficient additional financing. We did not make $25,000 of principal payments due on a convertible debenture and, as a result, this obligation can be placed in default by the holder. Our independent registered public accounting firm included an emphasis of a matter paragraph in its report included in this annual report on Form 10-K, which expressed substantial doubt about our ability to continue as a going concern. Our financial statements included herein do not include any adjustments related to this uncertainty.

We currently do not have any lending relationships with commercial banks and do not anticipate establishing such relationships in the foreseeable future due to our limited operations and assets. We believe that our focus should be on obtaining additional capital through the private placement of our securities. We are pursuing potential equity and/or debt investors and have from time to time engaged placement agents to assist us in this initiative. While we are pursuing the opportunities and actions described above, there can be no assurance that we will be successful in our efforts. If we are unable to secure additional capital, we will explore other strategic alternatives, including, but not limited to, the sale of Scivanta. Any additional equity financing may result in substantial dilution to our stockholders.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Scivanta is a smaller reporting company and is therefore not required to provide this information.

Item 4. Controls and Procedures

As required by Rule 13a-15 under the Exchange Act, as of the end of the period covered by this quarterly report on Form 10-Q, the Company carried out an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures. This evaluation was carried out under the supervision and with the participation of the Company’s management, including the Company’s President and Chief Executive Officer and the Company’s Executive Vice President, Chief Financial Officer and Secretary, who concluded that the Company’s disclosure controls and procedures are effective. There has been no change in the Company’s internal control over financial reporting during the Company’s last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in the Company’s reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the Company’s reports filed under the Exchange Act is accumulated and communicated to management, including the Company’s Chief Executive Officer and the Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

Scivanta is a smaller reporting company and is therefore not required to provide this information.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On June 22, 2016, the Company issued 129,032 shares of common stock to the May 2011 Debenture holder in satisfaction of $8,000 of interest due for the period commencing May 20, 2015 through May 19, 2016. In connection with this issuance of shares of common stock, Scivanta relied on the exemption from registration for a private transaction not involving a public distribution provided by Section 4(2) of the Securities Act.

Item 3. Defaults Upon Senior Securities

Not Applicable.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

Item 6. Exhibits

See Index of Exhibits Commencing on Page E-1.

SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

DATE:	SCIVANTA MEDICAL CORPORATION

September 13, 2016	By:	/s/ David R. LaVance
		David R. LaVance
		President and Chief Executive Officer

September 13, 2016	By:	/s/ Thomas S. Gifford
		Thomas S. Gifford
		Executive Vice President,
		Chief Financial Officer and Secretary

INDEX OF EXHIBITS

Exhibit
Number		Description of Exhibit

3.1		Amended and Restated Articles of Incorporation of Scivanta Medical Corporation, (the “Company”), which was filed in the Office of the Secretary of State of the State of Nevada on April 22, 2013 (incorporated by reference to Exhibit 3.1 to the Company’s current report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 22, 2013).

3.2		Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s quarterly report on Form 10-QSB for the quarter ended January 31, 2006, filed with the SEC on January 29, 2007).

4.1		Specimen stock certificate representing the Company’s common stock (incorporated by reference to Exhibit 4.1 to the Company’s quarterly report on Form 10-QSB for the quarter ended January 31, 2006, filed with the SEC on January 29, 2007).

4.2		Form of Convertible Debenture, dated as of February 1, 2007, issued to the following persons and in the following amounts: Jesse H. Austin, III ($50,000); Andrew O. Whiteman and Gwen C. Whiteman, JTWROS ($25,000); Jack W. Cumming ($25,000); Scott C. Withrow ($25,000); Terrence McQuade ($25,000); Steven J. Olsen ($25,000); and Marc G. Robinson and Joshua Goldfarb ($25,000) (incorporated by reference to Exhibit 4.8 to the Company’s quarterly report on Form 10-QSB for the quarter ended January 31, 2007, filed with the SEC on March 14, 2007).

4.3		Form of Addendum to Convertible Debenture, dated as of January 31, 2010, issued to the persons set forth in Exhibit 4.2 (incorporated by reference to Exhibit 4.3 to the Company’s annual report on Form 10-K for the fiscal year ended October 31, 2009, filed with the SEC on January 29, 2010).

4.4		Form of Addendum to Convertible Debenture, dated as of January 31, 2012, issued to certain persons set forth in Exhibit 4.2 (incorporated by reference to Exhibit 4.4 to the Company’s quarterly report on Form 10-Q for the quarter ended January 31, 2012, filed with the SEC on March 16, 2012).

4.5		8% Convertible Debenture, dated as of May 20, 2011, in the principal amount of $100,000 issued to Zanett Opportunity Fund, Ltd. (incorporated by reference to Exhibit 4.4 to the Company’s quarterly report on Form 10-Q for the quarter ended April 30, 2011, filed with the SEC on June 14, 2011).

4.6		8% Convertible Debenture, dated as of August 15, 2012, in the principal amount of $100,000 issued to Zanett Opportunity Fund, Ltd. (incorporated by reference to Exhibit 4.1 to the Company’s current report on Form 8-K filed with the SEC on August 21, 2012).

4.7		Form of 10% Convertible Debenture issued on: December 12, 2013 in the principal amount of $150,000; April 1, 2014 in the principal amount of $75,000; February 12, 2015 in the principal amount of $50,000; September 14, 2015 in the principal amount of $25,000; and January 4, 2016 in the principal amount of $50,000 (incorporated by reference to Exhibit 4.1 to the Company’s current reports on Form 8-K filed with the SEC on December 17, 2013).

E-1

Exhibit
Number		Description of Exhibit

10.1		The Company’s 2002 Equity Incentive Plan, adopted and effective January 1, 2002 (incorporated by reference to Exhibit B of the Company’s definitive proxy statement, filed with the SEC on June 10, 2002).

10.2		Sublease Agreement, dated February 1, 2007, between the Company and Century Capital Associates LLC (incorporated by reference to Exhibit 10.14 to the Company’s quarterly report on Form 10-QSB for the quarter ended January 31, 2007, filed with the SEC on March 14, 2007).

10.3		Amended and Restated Technology License Agreement between the Company and The Research Foundation of State University of New York for and on behalf of University of Buffalo, and Donald D. Hickey, M.D. and Clas E. Lundgren dated February 14, 2011 (incorporated by reference to Exhibit 10.8 to the Company’s annual report on Form 10-K for the fiscal year ended October 31, 2010, filed with the SEC on February 15, 2011).

10.3.1		First Addendum to the Amended and Restated Technology License Agreement between the Company and The Research Foundation for State University of New York for and on behalf of University of Buffalo, and Donald D. Hickey, M.D. and Clas E. Lundgren dated March 14, 2013 (incorporated by reference to Exhibit 10.3.1 to the Company’s quarterly report on Form 10-Q for the quarter ended January 31, 2013, filed with the SEC on March 18, 2013).

10.3.2		License Termination Agreement between the Company and The Research Foundation for State University of New York for and on behalf of University of Buffalo, and Donald D. Hickey, M.D. and Clas E. Lundgren dated January 22, 2016 (incorporated by reference to Exhibit 10.3.2 to the Company’s annual report on Form 10-K for the fiscal year ended October 31, 2015, filed with the SEC on January 27, 2016).

10.4		Stock Option Agreement and Notice of Grant, dated February 5, 2007, pursuant to which David R. LaVance was granted a non-qualified stock option to purchase up to 500,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.16 to the Company’s quarterly report on Form 10-QSB for the quarter ended January 31, 2007, filed with the SEC on March 14, 2007).

10.5		Stock Option Agreement and Notice of Grant, dated February 5, 2007, pursuant to which Thomas S. Gifford was granted a non-qualified stock option to purchase up to 500,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.17 to the Company’s quarterly report on Form 10-QSB for the quarter ended January 31, 2007, filed with the SEC on March 14, 2007).

10.6		Company’s 2007 Equity Incentive Plan, adopted and effective May 31, 2007 (incorporated by reference to Appendix to the Company’s definitive proxy statement, filed with the SEC on April 27, 2007).

10.7		Stock Option Agreement and Notice of Grant, dated January 1, 2008, pursuant to which David R. LaVance was granted a non-qualified stock option to purchase up to 100,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.21 to the Company’s current report on Form 8-K filed with the SEC on January 2, 2008).

E-2

Exhibit
Number		Description of Exhibit

10.8		Stock Option Agreement and Notice of Grant, dated January 1, 2008, pursuant to which Thomas S. Gifford was granted a non-qualified stock option to purchase up to 100,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.22 to the Company’s current report on Form 8-K filed with the SEC on January 2, 2008).

10.9		Executive Employment Agreement, dated as of January 1, 2008, between the Company and David R. LaVance (incorporated by reference to Exhibit 10.26 to the Company’s current report on Form 8-K filed with the SEC on January 2, 2008).

10.10		Executive Employment Agreement, dated as of January 1, 2008, between the Company and Thomas S. Gifford (incorporated by reference to Exhibit 10.27 to the Company’s current report on Form 8-K filed with the SEC on January 2, 2008).

10.11		Amendment No. 1 dated as of June 18, 2010 to the Executive Employment Agreement, dated as of January 1, 2008, between the Company and David R. LaVance (incorporated by reference to Exhibit 10.27 to the Company’s quarterly report on Form 10-Q for the quarter ended April 30, 2010, filed with the SEC on June 21, 2010).

10.12		Amendment No. 1 dated as of June 18, 2010 to the Executive Employment Agreement, dated as of January 1, 2008, between the Company and Thomas S. Gifford (incorporated by reference to Exhibit 10.28 to the Company’s quarterly report on Form 10-Q for the quarter ended April 30, 2010, filed with the SEC on June 21, 2010).

10.13		Amendment No. 2 dated as of January 3, 2012 to the Executive Employment Agreement, dated as of January 1, 2008, between the Company and David R. LaVance (incorporated by reference to Exhibit 10.23 to the Company’s annual report on Form 10-KSB for the fiscal year ended October 31, 2011, filed with the SEC on January 30, 2012).

10.14		Amendment No. 2 dated as of January 3, 2012 to the Executive Employment Agreement, dated as of January 1, 2008, between the Company and Thomas S. Gifford (incorporated by reference to Exhibit 10.24 to the Company’s annual report on Form 10-KSB for the fiscal year ended October 31, 2011, filed with the SEC on January 30, 2012).

10.15		Stock Option Agreement and Notice of Grant, dated January 21, 2009, pursuant to which David R. LaVance was granted a non-qualified stock option to purchase up to 25,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.32 to the Company’s annual report on Form 10-KSB for the fiscal year ended October 31, 2008, filed with the SEC on January 29, 2009).

10.16		Stock Option Agreement and Notice of Grant, dated January 21, 2009, pursuant to which Thomas S. Gifford was granted a non-qualified stock option to purchase up to 25,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.33 to the Company’s annual report on Form 10-KSB for the fiscal year ended October 31, 2008, filed with the SEC on January 29, 2009).

E-3

Exhibit
Number		Description of Exhibit

31.1		Section 302 Certification of Chief Executive Officer.

31.2		Section 302 Certification of Chief Financial Officer.

32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.

32.2		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.

101		The following materials from the Company’s quarterly report on Form 10-Q for the period ended July 31, 2016, formatted in Extensible Business Reporting Language (XBRL): (i) balance sheets; (ii) statements of operations; (iii) statements of cash flows; and (iv) notes to the financial statements.

E-4

EX-31.1 2 ex31-1.htm

EXHIBIT 31.1

CERTIFICATION

I, David R. LaVance, certify that:

1. I have reviewed this report on Form 10-Q of Scivanta Medical Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: September 13, 2016	By:	/s/ David R. LaVance
		David R. LaVance
		President and Chief Executive Officer

EX-31.2 3 ex31-2.htm

EXHIBIT 31.2

CERTIFICATION

I, Thomas S. Gifford, certify that:

1. I have reviewed this report on Form 10-Q of Scivanta Medical Corporation;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: September 13, 2016	By:	/s/ Thomas S. Gifford
		Thomas S. Gifford
		Executive Vice President,
		Chief Financial Officer and Secretary

EX-32.1 4 ex32-1.htm

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Scivanta Medical Corporation (the “Company”) on Form 10-Q for the period ended July 31, 2016, as filed with the Securities and Exchange Commission (the “Report”), I, David R. LaVance, President and Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) the Report fully complies with the requirements of §13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, 15 U.S.C. §78m or 78o(d), and,

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: September 13, 2016	By:	/s/ David R. LaVance
		David R. LaVance
		President and Chief Executive Officer

EX-32.2 5 ex32-2.htm

EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Scivanta Medical Corporation (the “Company”) on Form 10-Q for the period ended July 31, 2016, as filed with the Securities and Exchange Commission (the “Report”), I, Thomas S. Gifford, Executive Vice President, Chief Financial Officer and Secretary of the Company, do hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) the Report fully complies with the requirements of §13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, 15 U.S.C. §78m or 78o(d), and,

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: September 13, 2016	By:	/s/ Thomas S. Gifford
		Thomas S. Gifford
		Executive Vice President,
		Chief Financial Officer and Secretary

EX-101.INS 6 scvm-20160731.xml XBRL INSTANCE FILE 0001093285 2015-11-01 2016-07-31 0001093285 2016-09-09 0001093285 2016-07-31 0001093285 2015-10-31 0001093285 2014-11-01 2015-07-31 0001093285 2014-10-31 0001093285 2015-07-31 0001093285 us-gaap:StockOptionMember 2015-11-01 2016-07-31 0001093285 us-gaap:WarrantMember 2015-11-01 2016-07-31 0001093285 SCVM:DonaldDHickeyMember SCVM:ScmsLicenseAgreementMember 2011-02-13 2011-02-14 0001093285 SCVM:DonaldDHickeyMember SCVM:ScmsLicenseAgreementMember SCVM:SxMonthPeriodMember 2011-02-13 2011-02-14 0001093285 SCVM:DonaldDHickeyMember SCVM:ScmsLicenseAgreementMember SCVM:AfterClosingAnySingleFinancingMember 2011-02-13 2011-02-14 0001093285 SCVM:DonaldDHickeyMember SCVM:ScmsLicenseAgreementMember SCVM:AfterFirstCommercialSaleOfLicensedTechnologyMember 2011-02-13 2011-02-14 0001093285 SCVM:DonaldDHickeyMember SCVM:LicenseTerminationAgreementMember 2016-01-22 0001093285 SCVM:CenturyCapitalAssociatesLLCMember 2007-02-01 0001093285 SCVM:CenturyCapitalAssociatesLLCMember 2015-11-01 2016-07-31 0001093285 SCVM:DonaldDHickeyMember SCVM:LicenseAgreementMember 2016-07-31 0001093285 SCVM:DonaldDHickeyMember SCVM:LicenseTerminationAgreementMember 2015-11-01 2016-07-31 0001093285 SCVM:FebruaryTwothousandSevenDebenturesMember SCVM:IndividualInvestorsMember 2007-02-07 2007-02-08 0001093285 SCVM:FebruaryTwothousandSevenDebenturesMember SCVM:IndividualInvestorsMember 2007-02-08 0001093285 SCVM:FebruaryTwothousandSevenDebenturesMember 2012-01-10 2012-01-11 0001093285 SCVM:FebruaryTwothousandSevenDebenturesMember 2016-05-01 2016-07-31 0001093285 SCVM:FebruaryTwothousandSevenDebenturesMember 2015-11-01 2016-07-31 0001093285 SCVM:FebruaryTwothousandSevenDebenturesMember 2016-07-31 0001093285 SCVM:InstitutionalInvestorMember SCVM:MayTwoThousandElevenConvertibleDebentureMember 2011-05-19 2011-05-20 0001093285 SCVM:InstitutionalInvestorMember SCVM:MayTwoThousandElevenConvertibleDebentureMember 2011-05-20 0001093285 SCVM:MayTwoThousandElevenConvertibleDebentureMember 2015-11-01 2016-07-31 0001093285 SCVM:MayTwoThousandElevenConvertibleDebentureMember 2014-11-01 2015-07-31 0001093285 SCVM:MayTwoThousandElevenConvertibleDebentureMember 2016-07-31 0001093285 SCVM:InstitutionalInvestorMember SCVM:AugustTwoThousandTwelveConvertibleDebentureMember 2012-08-14 2012-08-15 0001093285 SCVM:InstitutionalInvestorMember SCVM:AugustTwoThousandTwelveConvertibleDebentureMember 2012-08-15 0001093285 SCVM:AugustTwoThousandTwelveConvertibleDebentureMember 2015-11-01 2016-07-31 0001093285 SCVM:AugustTwoThousandTwelveConvertibleDebentureMember 2014-11-01 2015-07-31 0001093285 SCVM:AugustTwoThousandTwelveConvertibleDebentureMember 2016-07-31 0001093285 SCVM:DecemberTwoThousandThirteenAndAprilTwoThousandFourteenConvertibleDebenturesAndWarrantsMember 2013-12-11 2013-12-12 0001093285 SCVM:DecemberTwoThousandThirteenAndAprilTwoThousandFourteenConvertibleDebenturesAndWarrantsMember 2015-11-01 2016-07-31 0001093285 SCVM:IndividualInvestorsMember SCVM:FebruaryTwoThousandFifteenConvertibleDebentureAndWarrantMember 2015-02-11 2015-02-12 0001093285 SCVM:IndividualInvestorsMember SCVM:FebruaryTwoThousandFifteenConvertibleDebentureAndWarrantMember 2015-02-12 0001093285 SCVM:FebruaryTwoThousandFifteenConvertibleDebentureAndWarrantMember 2015-02-11 2015-02-12 0001093285 SCVM:FebruaryTwoThousandFifteenConvertibleDebentureAndWarrantMember 2015-11-01 2016-07-31 0001093285 SCVM:SeptemberTwothousandFifteenConvertibleDebenturesAndWarrantsMember SCVM:ThreeIndividualInvestorsMember 2015-09-12 2015-09-14 0001093285 SCVM:SeptemberTwothousandFifteenConvertibleDebenturesAndWarrantsMember SCVM:ThreeIndividualInvestorsMember 2015-09-14 0001093285 SCVM:SeptemberTwothousandFifteenConvertibleDebenturesAndWarrantsMember 2015-09-12 2015-09-14 0001093285 SCVM:SeptemberTwothousandFifteenConvertibleDebenturesAndWarrantsMember 2015-11-01 2016-07-31 0001093285 SCVM:IndividualInvestorsMember SCVM:JanuaryTwoThousandSixteenDebentureAndWarrantMember 2016-01-02 2016-01-04 0001093285 SCVM:IndividualInvestorsMember SCVM:JanuaryTwoThousandSixteenDebentureAndWarrantMember 2016-01-04 0001093285 SCVM:JanuaryTwoThousandSixteenDebentureDividedMember 2016-01-02 2016-01-04 0001093285 SCVM:JanuaryTwoThousandSixteenDebentureDividedMember 2015-11-01 2016-07-31 0001093285 us-gaap:WarrantMember 2014-11-01 2015-07-31 0001093285 us-gaap:EmployeeStockOptionMember 2014-11-01 2015-07-31 0001093285 us-gaap:ConvertibleDebtSecuritiesMember 2014-11-01 2015-07-31 0001093285 us-gaap:ConvertibleDebtSecuritiesMember 2015-11-01 2016-07-31 0001093285 us-gaap:EmployeeStockOptionMember 2015-11-01 2016-07-31 0001093285 SCVM:EquityIncentivePlanOneMember 2013-12-01 2013-12-27 0001093285 SCVM:EquityIncentivePlanMember 2016-07-31 0001093285 SCVM:EquityIncentivePlanOneMember 2007-05-31 0001093285 SCVM:EquityIncentivePlanMember 2002-07-05 0001093285 SCVM:EquityIncentivePlanOneMember 2016-07-31 0001093285 us-gaap:StockOptionMember 2014-11-01 2015-07-31 0001093285 us-gaap:StockOptionMember 2015-07-31 0001093285 us-gaap:StockOptionMember 2015-10-31 0001093285 us-gaap:StockOptionMember 2016-07-31 0001093285 us-gaap:WarrantMember 2015-10-31 0001093285 us-gaap:WarrantMember 2016-07-31 0001093285 SCVM:ExercisePriceTwoMember us-gaap:StockOptionMember 2014-11-01 2015-07-31 0001093285 SCVM:ExercisePriceOneMember us-gaap:StockOptionMember 2014-11-01 2015-07-31 0001093285 SCVM:ExercisePriceOneMember us-gaap:StockOptionMember 2015-07-31 0001093285 SCVM:ExercisePriceTwoMember us-gaap:StockOptionMember 2015-07-31 0001093285 SCVM:EquityIncentivePlansMember 2015-11-01 2016-07-31 0001093285 SCVM:EquityIncentivePlansMember us-gaap:MaximumMember 2015-11-01 2016-07-31 0001093285 SCVM:DecemberTwoThousandThirteenDebenturesMember SCVM:TwoIndividualInvestorsMember 2013-12-12 0001093285 SCVM:DecemberTwoThousandThirteenDebenturesMember SCVM:TwoIndividualInvestorsMember 2013-12-11 2013-12-12 0001093285 SCVM:AprilTwoThousandFourteenDebenturesMember SCVM:OneIndividualInvestorsMember 2013-12-12 0001093285 SCVM:AprilTwoThousandFourteenDebenturesMember SCVM:OneIndividualInvestorsMember 2013-12-11 2013-12-12 0001093285 2016-05-01 2016-07-31 0001093285 2015-05-01 2015-07-31 0001093285 SCVM:CenturyCapitalAssociatesLLCMember 2016-07-31 0001093285 SCVM:FebruaryTwothousandSevenDebenturesMember 2016-03-30 2016-03-31 0001093285 SCVM:FebruaryTwothousandSevenDebenturesMember 2016-03-31 0001093285 SCVM:FebruaryTwothousandSevenDebenturesMember 2015-05-01 2015-07-31 0001093285 SCVM:FebruaryTwothousandSevenDebenturesMember 2014-11-01 2015-07-31 0001093285 SCVM:MayTwoThousandElevenConvertibleDebentureMember 2016-03-30 2016-03-31 0001093285 SCVM:MayTwoThousandElevenConvertibleDebentureMember 2016-03-31 0001093285 SCVM:MayTwoThousandElevenConvertibleDebentureMember 2016-05-01 2016-07-31 0001093285 SCVM:MayTwoThousandElevenConvertibleDebentureMember 2015-05-01 2015-07-31 0001093285 SCVM:AugustTwoThousandTwelveConvertibleDebentureMember 2016-03-30 2016-03-31 0001093285 SCVM:AugustTwoThousandTwelveConvertibleDebentureMember 2016-03-31 0001093285 SCVM:AugustTwoThousandTwelveConvertibleDebentureMember 2016-05-01 2016-07-31 0001093285 SCVM:AugustTwoThousandTwelveConvertibleDebentureMember 2015-05-01 2015-07-31 0001093285 SCVM:DecemberTwoThousandThirteenAndAprilTwoThousandFourteenConvertibleDebenturesAndWarrantsMember 2016-03-30 2016-03-31 0001093285 SCVM:DecemberTwoThousandThirteenAndAprilTwoThousandFourteenConvertibleDebenturesAndWarrantsMember 2016-03-31 0001093285 SCVM:DecemberTwoThousandThirteenAndAprilTwoThousandFourteenConvertibleDebenturesAndWarrantsMember us-gaap:MinimumMember 2016-07-31 0001093285 SCVM:DecemberTwoThousandThirteenAndAprilTwoThousandFourteenConvertibleDebenturesAndWarrantsMember us-gaap:MaximumMember 2016-07-31 0001093285 SCVM:DecemberTwoThousandThirteenAndAprilTwoThousandFourteenConvertibleDebenturesAndWarrantsMember 2016-05-01 2016-07-31 0001093285 SCVM:DecemberTwoThousandThirteenAndAprilTwoThousandFourteenConvertibleDebenturesAndWarrantsMember 2015-05-01 2015-07-31 0001093285 SCVM:DecemberTwoThousandThirteenAndAprilTwoThousandFourteenConvertibleDebenturesAndWarrantsMember 2014-11-01 2015-07-31 0001093285 SCVM:FebruaryTwoThousandFifteenConvertibleDebentureAndWarrantMember 2016-03-30 2016-03-31 0001093285 SCVM:FebruaryTwoThousandFifteenConvertibleDebentureAndWarrantMember 2016-03-31 0001093285 SCVM:FebruaryTwoThousandFifteenConvertibleDebentureAndWarrantMember us-gaap:MinimumMember 2016-03-31 0001093285 SCVM:FebruaryTwoThousandFifteenConvertibleDebentureAndWarrantMember us-gaap:MaximumMember 2016-03-31 0001093285 SCVM:FebruaryTwoThousandFifteenConvertibleDebentureAndWarrantMember 2016-05-01 2016-07-31 0001093285 SCVM:FebruaryTwoThousandFifteenConvertibleDebentureAndWarrantMember 2014-11-01 2015-07-31 0001093285 SCVM:FebruaryTwoThousandFifteenConvertibleDebentureAndWarrantMember 2015-05-01 2015-07-31 0001093285 SCVM:SeptemberTwothousandFifteenConvertibleDebenturesAndWarrantsMember 2016-03-30 2016-03-31 0001093285 SCVM:SeptemberTwothousandFifteenConvertibleDebenturesAndWarrantsMember 2016-03-31 0001093285 SCVM:SeptemberTwothousandFifteenConvertibleDebenturesAndWarrantsMember 2016-05-01 2016-07-31 0001093285 SCVM:JanuaryTwoThousandSixteenDebentureDividedMember 2016-03-30 2016-03-31 0001093285 SCVM:JanuaryTwoThousandSixteenDebentureDividedMember 2016-03-31 0001093285 SCVM:JanuaryTwoThousandSixteenDebentureDividedMember 2016-05-01 2016-07-31 0001093285 SCVM:SubleaseAgreementMember 2015-11-01 2016-07-31 0001093285 SCVM:SubleaseAgreementMember 2016-07-31 0001093285 SCVM:MayTwoThousandElevenConvertibleDebentureMember 2016-06-21 2016-06-22 0001093285 SCVM:MayTwoThousandElevenConvertibleDebentureMember 2016-06-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares utr:sqft xbrli:pure SCVM:StockOptionPlans SCIVANTA MEDICAL CORP 10-Q 2016-07-31 false --10-31 Smaller Reporting Company Q3 2016

225000

694791

25000

100000

.001

20000000

0.001

500000000

20934717

6359055

20934717

6359055

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; font: 11pt/115% Calibri, Helvetica, Sans-Serif">1.</td> <td style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify">Basis of Presentation</td></tr> </table>   The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant recurring operating losses and negative cash flows from operations. The Company had a working capital deficiency of $397,079 and an accumulated deficit of $24,649,593 as of July 31, 2016. The Company has not made the $25,000 principal payment due on a convertible debenture and, as a result, that obligation can be placed in default by the holder. The Company also has no lending relationships with commercial banks and is dependent on the completion of a financing involving the private placement of its securities in order to continue operations. These factors raise substantial doubt about the Companys ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.   On November 10, 2006, the Company licensed the exclusive world-wide rights to develop, manufacture and distribute certain proprietary technologies known as the Scivanta Cardiac Monitoring System (the SCMS), a minimally invasive two-balloon esophageal catheter system used to monitor cardiac performance. On January 22, 2016, the Company and the Licensor (as hereinafter defined) terminated the SCMS license agreement and, as a result, all property related to the SCMS held by the Company, including intellectual property, was assigned and returned to the Licensor (see Note 2).   The Companys strategy for business development is focused on the acquisition, through licensing or purchasing, of medical devices, pharmaceuticals and other proprietary technologies, patented products or services. Any such acquisitions will be contingent upon the Companys ability to secure the financing required to fund such acquisitions.   The Company continues to seek equity and/or debt investors and from time to time engages placement agents to assist the Company in this initiative. Effective November 1, 2011, each of the Companys officers agreed to waive the annual base salary due to them and each of the Companys directors agreed to waive the annual retainer and meeting fees due to them until the Company is able to raise sufficient capital that would provide the Company with the ability to pay cash compensation to its officers and directors. The Company has also paid certain obligations with shares of its common stock and has deferred certain other vendor payments until the Company secures sufficient additional debt or equity financing.   While the Company is pursuing the opportunities and actions described above, there can be no assurance that it will be successful in its efforts. If the Company is unable to secure additional capital, it will explore other strategic alternatives, including, but not limited to, the sale of the Company. Any additional equity financing may result in substantial dilution to our stockholders.

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 7%; font: 11pt/115% Calibri, Helvetica, Sans-Serif">4.</td> <td style="width: 93%; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify">Note Payable</td></tr> </table>   Pursuant to the License Agreement, a cash payment of $105,000 was payable to Hickey. Pursuant to the License Termination Agreement, the Licensor released the Company from any obligation regarding payment of the $105,000 to Hickey (see Note 2). Accordingly, for the nine months ended July 31, 2016, the Company recorded a $105,000 gain on the settlement of the note payable.

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 0%"> </td> <td style="width: 48px; font: 11pt/115% Calibri, Helvetica, Sans-Serif">8.</td> <td style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify">Stockholders Equity</td></tr> </table>   Issuance of Common Stock as Payment of Interest on Convertible Debenture   On June 22, 2016, the Company issued 129,032 shares of common stock to the May 2011 Debenture holder in satisfaction of $8,000 of interest due for the period commencing May 20, 2015 through May 19, 2016 (see Note 5).   Stock Option Plans   The Company currently has two stock option plans in place: the 2002 Equity Incentive Plan and the 2007 Equity Incentive Plan (collectively, the Equity Incentive Plans). The 2002 Equity Incentive Plan was approved by the stockholders on July 5, 2002. The aggregate number of shares of common stock which could have been awarded under the 2002 Equity Incentive Plan was 200,000. As of July 31, 2016, options to purchase 110,000 shares of the Companys common stock were outstanding under the 2002 Equity Incentive Plan. As a result of the adoption of the Companys 2007 Equity Incentive Plan, no further awards are permitted under the 2002 Equity Incentive Plan.   On May 31, 2007, the stockholders approved the Companys 2007 Equity Incentive Plan. The original aggregate number of shares of common stock which could be awarded under the 2007 Equity Incentive Plan was 300,000 shares, subject to adjustment as provided in the 2007 Equity Incentive Plan. Effective December 27, 2013, as permitted under the 2007 Equity Incentive Plan, the Companys board of directors increased the number of shares of common stock that could be awarded under the 2007 Equity Incentive Plan to 814,408 shares. As of July 31, 2016, options to purchase 83,332 shares of the Companys common stock were outstanding under the 2007 Equity Incentive Plan and up to 731,076 shares of the Companys common stock remain available for awards under the 2007 Equity Incentive Plan.   Stock option awards under the Equity Incentive Plans were granted at prices as determined by the Companys compensation committee, but such prices were not less than the fair market value of the Companys common stock on the date of grant. Stock options granted and outstanding include only non-qualified stock options that vested over a period of up to five years and have a maximum term of ten years from the date of grant.   A summary of stock option transactions for employees and directors under the Equity Incentive Plans during the nine months ended July 31, 2016 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Stock Option Shares</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Exercise Price Per Common Share</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Aggregate Intrinsic Value</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 55%; line-height: 115%">Outstanding at October 31, 2015</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 12%; text-align: right; line-height: 115%">203,332</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">1.70</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%"></td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Granted during the period</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercised during the period</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Expired during the period</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(10,000</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.80</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Outstanding at July 31, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">193,332</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.74</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Exercisable at July 31, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">193,332</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.74</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercisable at October 31, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">203,332</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.70</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> </table>   Information with respect to stock options outstanding and stock options exercisable as of July 31, 2016 that were granted to employees is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Stock Options Outstanding</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Stock Options Exercisable</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid"> Exercise Price</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Number of Shares Available Under Outstanding Stock Options</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Exercise Price Per Common Share</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Remaining Contractual Life (Years)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Shares Available for Purchase Under Outstanding Stock Options</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Exercise Price Per Common Share</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Remaining Contractual Life (Years)</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">1.40</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 18%; text-align: right; line-height: 115%">83,332</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">1.40</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 11%; text-align: right; line-height: 115%">2.1</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">83,332</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">1.40</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">2.1</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">2.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">110,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">2.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0.5</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">110,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">2.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0.5</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">193,332</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.74</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.2</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">193,332</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.74</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.2</td> <td style="line-height: 115%"> </td></tr> </table>   Warrant to Purchase Common Stock   A summary of warrant transactions during the nine months ended July 31, 2016 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Warrant Shares</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Exercise Price Per Common Share</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Aggregate Intrinsic Value</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 55%; line-height: 115%">Outstanding at October 31, 2015</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 12%; text-align: right; line-height: 115%">750,000</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">0.12</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%"></td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Issued during the period</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">153,846</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.07</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercised during the period</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Expired during the period</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Outstanding at July 31, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">903,846</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.11</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Exercisable at July 31, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">673,077</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.13</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercisable at October 31, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">596,154</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.13</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> </table>   As of July 31, 2016, the weighted average remaining contractual life for warrants outstanding was 1.6 years and for warrants exercisable was 1.3 years.

397079

25000

250000

25000

100000

50000

25000

50000

150000

75000

105000

50000

55000

105000

3000000

105000

2000

P60D

5000

58464

53750

36899

20229

19057

5229

135000

15000

284865 23920

105000

0.08

0.10

2010-01-31

2014-05-20

2015-08-15

2014-12-12

2015-04-01

50000

175000

225000

50000

25000

50000

856934

128205

161538

4223392

856270

405585

787566

129032

504

7330

6006

5985

6006

5985

9269

3788

4545

4696

4033

11968

2016

2017

2016

2017

5671

24566

5838

3178

0.20 0.20 0.20 0.20

36796

5983

4022

3504

0.065

0.13

0.065

0.13

0.065

903846

673077

203332

2782051

593750

193332

300000

200000

814408

731076

P1Y7M6D

110000

83332

203332

193332

750000

903846

10000

193332

203332

673077

596154

1.70

1.74

0.12

0.11

0.80

1.74

1.70

0.13

153846

0.07

2.00

1.40

193332

83332

110000

1.74

1.40

2.00

P1Y2M12D

P6M

P2Y1M6D

193332

83332

110000

1.74

1.40

2.00

P1Y2M12D

P6M

P2Y1M6D

A summary of stock option transactions for employees and directors under the Equity Incentive Plans during the nine months ended July 31, 2016 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Stock Option Shares</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Exercise Price Per Common Share</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Aggregate Intrinsic Value</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 55%; line-height: 115%">Outstanding at October 31, 2015</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 12%; text-align: right; line-height: 115%">203,332</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">1.70</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%"></td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Granted during the period</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercised during the period</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Expired during the period</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(10,000</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.80</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Outstanding at July 31, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">193,332</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.74</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Exercisable at July 31, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">193,332</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.74</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercisable at October 31, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">203,332</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.70</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"></td></tr> </table>

A summary of warrant transactions during the nine months ended July 31, 2016 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Warrant Shares</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Exercise Price Per Common Share</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Aggregate Intrinsic Value</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 55%; line-height: 115%">Outstanding at October 31, 2015</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 12%; text-align: right; line-height: 115%">750,000</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">0.12</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%"></td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Issued during the period</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">153,846</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.07</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercised during the period</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Expired during the period</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Outstanding at July 31, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">903,846</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.11</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Exercisable at July 31, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">673,077</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.13</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercisable at October 31, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">596,154</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.13</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"></td></tr> </table>

Information with respect to stock options outstanding and stock options exercisable as of July 31, 2016 that were granted to employees is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Stock Options Outstanding</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Stock Options Exercisable</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid"> Exercise Price</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Number of Shares Available Under Outstanding Stock Options</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Exercise Price Per Common Share</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Remaining Contractual Life (Years)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Shares Available for Purchase Under Outstanding Stock Options</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Exercise Price Per Common Share</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Remaining Contractual Life (Years)</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">1.40</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 18%; text-align: right; line-height: 115%">83,332</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">1.40</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 11%; text-align: right; line-height: 115%">2.1</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">83,332</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">1.40</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">2.1</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">2.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">110,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">2.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0.5</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">110,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">2.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0.5</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">193,332</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.74</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.2</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">193,332</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.74</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.2</td> <td style="line-height: 115%"></td></tr> </table>

P3Y

P1Y

2017-03-31 2017-03-31 2016-02-12 2016-09-14 2017-01-04 2012-01-31 2015-05-20

P5Y

P10Y

36796

5983

1705

4022

-3504

3504

7738

3523

1918

SCVM 7548522 7027140

7027140

997

1630

7810

34302

16000

49521

5658

1363

1192

8000

-48257 40122 8135 40122 8135

P1Y3M18D

0001093285

32887

28627

4739

6969

429966

1390402

105000

429966

1285402

34937

119046

44149

369479

125880

102086

32887

28627

-397079

-1361775

-24649593

-24448728

24231579

23080594

20935

6359

12093663

6359055

20861786

6359055

-0.02

-0.04

0.00

-0.01

-200865

-231321

-69379

-79745

41640

54342

4536

16916

-110968

-176979

-64843

-62829

105000

215968

176979

64843

62829

8713

11261

-43510

-62584

47927

38582

131434

116830

23794

-1719

-2230

-3783

50000

456764 657036 3504 7610

500

28148

21658

26114

13530

6490

-12584

20934717

EX-101.SCH 7 scvm-20160731.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Amended and Restated SCMS License Agreement link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Note Payable link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Convertible Debentures link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Net Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Amended and Restated SCMS License Agreement (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Note Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Convertible Debentures (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Net Loss Per Common Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Stockholders' Equity - Schedule of Stock Options Outstanding and Stock Options Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 scvm-20160731_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 scvm-20160731_def.xml XBRL DEFINITION FILE EX-101.LAB 10 scvm-20160731_lab.xml XBRL LABEL FILE Stock Option [Member] Major Types Of Debt and Equity Securities [Axis] Warrant [Member] Antidilutive Securities [Axis] Donald D. Hickey [Member] Related Party [Axis] SCMS License Agreement [Member] Agreement [Axis] Six Month Period [Member] Scenario [Axis] After Closing Any Single Financing [Member] After First Commercial Sale of Licensed Technology [Member] License Termination Agreement [Member] Century Capital Associates LLC [Member] License Agreement [Member] February 2007 Debentures [Member] Debt Instrument [Axis] Individual Investors [Member] Institutional Investor [Member] May 2011 Convertible Debenture [Member] August 2012 Convertible Debenture [Member] December 2013 and April 2014 Convertible Debentures and Warrants [Member] February 2015 Convertible Debenture and Warrant [Member] September 2015 Convertible Debentures and Warrants [Member] Three Individual Investors [Member] January 2016 Debenture and Warrant [Member] January 2016 Debenture Divided [Member] Stock Option [Member] Convertible Debt Securities [Member] 2007 Equity Incentive Plan [Member] 2002 Equity Incentive Plan [Member] Exercise Price Two [Member] Exercise Price Range [Axis] Exercise Price One [Member] Equity Incentive Plans [Member] Plan Name [Axis] Maximum [Member] Range [Axis] December 2013 Debentures [Member] Two Individual Investors [Member] April 2014 Debentures [Member] Two Individual Investors [Member] Minimum [Member] Sublease Agreement [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current assets: Cash Prepaid expenses Total current assets and total assets Liabilities and Stockholders' Deficiency Current liabilities: Accounts payable Accounts payable - related party Accrued expenses Convertible debentures Total current liabilities Note payable Total liabilities Commitments Stockholders' deficiency: Preferred stock, $.001 par value; 20,000,000 shares authorized; no shares issued Common stock, $.001 par value; 500,000,000 shares authorized; 20,934,717 and 6,359,055 shares issued and outstanding, respectively Additional paid-in capital Accumulated deficit Total stockholders' deficiency Total liabilities and stockholders' deficiency Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Operating expenses: General and administrative Gain on settlement of note payable Loss from operations Interest expense Loss on inducement of convertible debentures Net loss Net loss per common share, basic and diluted Weighted average number of common shares outstanding, basic and diluted Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Accretion of interest on convertible debentures Loss on inducement of convertible debentures Changes in operating assets and liabilities: Prepaid expenses Accounts payable Accounts payable - related party Accrued expenses Net cash used in operating activities Cash flows from financing activities: Proceeds from issuance of convertible debenture Increase (decrease) in cash Cash - beginning of period Cash - end of period Supplemental disclosure of cash flow information: Cash paid for income taxes Noncash financing activities: Discount recorded in connection with issuance of convertible debenture Issuance of 7,548,522 shares of common stock as payment of principal and interest due on convertible debentures Issuance of 7,027,140 shares of common stock as settlement of accounts payable - related party Common stock shares issued as payment for principal and interest due on convertible debentures Common stock shares issued as setttlement of certain accounts payable related party Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Presentation Amended And Restated Scms License Agreement Amended and Restated SCMS License Agreement Related Party Transactions [Abstract] Related Party Transactions Debt Disclosure [Abstract] Note Payable Convertible Debentures Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock-Based Compensation Earnings Per Share [Abstract] Net Loss Per Common Share Equity [Abstract] Stockholders' Equity Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Major Types of Debt and Equity Securities [Axis] Schedule of Stock Option Activity Schedule of Stock Options Outstanding and Stock Options Exercisable Working capital deficiency Accumulated deficit Principal payment due on convertible debenture Statement [Table] Statement [Line Items] AgreementAxis [Axis] Cash payment to related party Maximum closing single financing amount Termination of license agreement Area of office space Notice period to terminate sublease agreement Monthly rental fee Sublease agreement expenses Rent due under the Sublease Agreement Other expenses included in accounts payable - related party Number of shares issued Cash payment to related party Payment to related party Gain on settlement of note payable Debt instruments principal amount Debentures bear interest at rate Debt maturity date Debt initially extended date Debt instruments conversion into share Debt instruments conversion into shares value Accrued interest Interest expense on debt Convertible debt carrying value net Debt instrument new maturity date Debt maturity term Percentage of common stock equal aggregate principal amount Debt discount Unamortized discount Accreted interest expense Proceeds from equity securities Percentage of share price paid by purchaser Percentage of share conversion price of any instrument convertible into shares Conversion price per share Loss on conversion of convertible debt Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive shares which were not included in computation of diluted per share Number of stock option plans Aggregate number of common stock shares awarded Stock option plan outstanding Increased in number of common stock shares awarded Common stock available for awards under equity incentive plan Stock options vested over period Stock options grant date term Weighted average warrants outstanding contractual life Weighted average warrants exercisable contractual life Stock Option/Warrants Shares, Outstanding Beginning Balance Stock Option/Warrants Shares, Granted/Issued during the period Stock Option/Warrants Shares, Exercised during the period EX-101.PRE 11 scvm-20160731_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Jul. 31, 2016	Sep. 09, 2016
Document And Entity Information
Entity Registrant Name	SCIVANTA MEDICAL CORP
Entity Central Index Key	0001093285
Document Type	10-Q
Document Period End Date	Jul. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		20,934,717
Trading Symbol	SCVM
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2016

XML 13 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets (Unaudited) - USD ($)	Jul. 31, 2016	Oct. 31, 2015
Current assets:
Cash	$ 28,148	$ 21,658
Prepaid expenses	4,739	6,969
Total current assets and total assets	32,887	28,627
Current liabilities:
Accounts payable	125,880	102,086
Accounts payable - related party	44,149	369,479
Accrued expenses	34,937	119,046
Convertible debentures	225,000	694,791
Total current liabilities	429,966	1,285,402
Note payable		105,000
Total liabilities	429,966	1,390,402
Commitments
Stockholders' deficiency:
Preferred stock, $.001 par value; 20,000,000 shares authorized; no shares issued
Common stock, $.001 par value; 500,000,000 shares authorized; 20,934,717 and 6,359,055 shares issued and outstanding, respectively	20,935	6,359
Additional paid-in capital	24,231,579	23,080,594
Accumulated deficit	(24,649,593)	(24,448,728)
Total stockholders' deficiency	(397,079)	(1,361,775)
Total liabilities and stockholders' deficiency	$ 32,887	$ 28,627

XML 14 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Parenthetical) - $ / shares	Jul. 31, 2016	Oct. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value	$ .001	$ .001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	20,934,717	6,359,055
Common stock, shares outstanding	20,934,717	6,359,055

XML 15 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
Statements of Operations (Unaudited) - USD ($)	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015
Income Statement [Abstract]
Revenue
Operating expenses:
General and administrative	64,843	62,829	215,968	176,979
Gain on settlement of note payable			(105,000)
Loss from operations	(64,843)	(62,829)	(110,968)	(176,979)
Interest expense	(4,536)	(16,916)	(41,640)	(54,342)
Loss on inducement of convertible debentures			(48,257)
Net loss	$ (69,379)	$ (79,745)	$ (200,865)	$ (231,321)
Net loss per common share, basic and diluted	$ 0.00	$ (0.01)	$ (0.02)	$ (0.04)
Weighted average number of common shares outstanding, basic and diluted	20,861,786	6,359,055	12,093,663	6,359,055

XML 16 R5.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
Statements of Cash Flows (Unaudited) - USD ($)	Jul. 31, 2016	Jul. 31, 2015
Cash flows from operating activities:
Net loss	$ (200,865)	$ (231,321)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on settlement of note payable	(105,000)
Accretion of interest on convertible debentures	8,713	11,261
Loss on inducement of convertible debentures	48,257
Changes in operating assets and liabilities:
Prepaid expenses	2,230	3,783
Accounts payable	23,794	(1,719)
Accounts payable - related party	131,434	116,830
Accrued expenses	47,927	38,582
Net cash used in operating activities	(43,510)	(62,584)
Cash flows from financing activities:
Proceeds from issuance of convertible debenture	50,000	50,000
Increase (decrease) in cash	6,490	(12,584)
Cash - beginning of period	21,658	26,114
Cash - end of period	28,148	13,530
Supplemental disclosure of cash flow information:
Cash paid for income taxes	500	500
Noncash financing activities:
Discount recorded in connection with issuance of convertible debenture	3,504	7,610
Issuance of 7,548,522 shares of common stock as payment of principal and interest due on convertible debentures	657,036
Issuance of 7,027,140 shares of common stock as settlement of accounts payable - related party	$ 456,764

XML 17 R6.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows (Parenthetical) - shares	9 Months Ended
Statements of Cash Flows (Parenthetical) - shares	Jul. 31, 2016	Jul. 31, 2015
Statement of Cash Flows [Abstract]
Common stock shares issued as payment for principal and interest due on convertible debentures	7,548,522
Common stock shares issued as setttlement of certain accounts payable related party	7,027,140

XML 18 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation

9 Months Ended

Jul. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

1.	Basis of Presentation

XML 19 R8.htm IDEA: XBRL DOCUMENT

Amended and Restated SCMS License Agreement

9 Months Ended

Jul. 31, 2016

Amended And Restated Scms License Agreement

Amended and Restated SCMS License Agreement

2.	Amended and Restated SCMS License Agreement

XML 20 R9.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Jul. 31, 2016

Related Party Transactions

Related Party Transactions

XML 21 R10.htm IDEA: XBRL DOCUMENT

Note Payable

9 Months Ended

Jul. 31, 2016

Debt Disclosure [Abstract]

Note Payable

4.	Note Payable

XML 22 R11.htm IDEA: XBRL DOCUMENT

Convertible Debentures

9 Months Ended

Jul. 31, 2016

Debt Disclosure [Abstract]

Convertible Debentures

Convertible Debentures

February 2007 Convertible Debentures

May 2011 Convertible Debenture

August 2012 Convertible Debenture

December 2013 and April 2014 Convertible Debentures and Warrants

February 2015 Convertible Debenture and Warrant

September 2015 Convertible Debentures and Warrants

For the three and nine months ended July 31, 2016, the Company recorded a total of $0 and $4,545 ($3,504 accreted), respectively, of interest expense related to the September 2015 Debentures.

January 2016 Convertible Debenture and Warrant

For the three and nine months ended July 31, 2016, the Company recorded a total of $0 and $4,696 ($3,504 accreted), respectively, of interest expense related to the January 2016 Debenture.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

9 Months Ended

Jul. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

Stock-Based Compensation

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share

9 Months Ended

Jul. 31, 2016

Earnings Per Share [Abstract]

Net Loss Per Common Share

Net Loss Per Common Share

XML 25 R14.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Jul. 31, 2016

Equity [Abstract]

Stockholders' Equity

Stockholders’ Equity

Issuance of Common Stock as Payment of Interest on Convertible Debenture

Stock Option Plans

A summary of stock option transactions for employees and directors under the Equity Incentive Plans during the nine months ended July 31, 2016 is as follows:

	Stock Option Shares			Weighted Average Exercise Price Per Common Share		Aggregate Intrinsic Value
Outstanding at October 31, 2015		203,332		$	1.70	$	—
Granted during the period		—			—
Exercised during the period		—			—
Expired during the period		(10,000	)	$	0.80
Outstanding at July 31, 2016		193,332		$	1.74	$	—
Exercisable at July 31, 2016		193,332		$	1.74	$	—
Exercisable at October 31, 2015		203,332		$	1.70	$	—

Information with respect to stock options outstanding and stock options exercisable as of July 31, 2016 that were granted to employees is as follows:

		Stock Options Outstanding						Stock Options Exercisable
Exercise Price		Number of Shares Available Under Outstanding Stock Options		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)		Number of Shares Available for Purchase Under Outstanding Stock Options		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)

$	1.40		83,332	$	1.40		2.1		83,332	$	1.40		2.1
$	2.00		110,000	$	2.00		0.5		110,000	$	2.00		0.5
			193,332	$	1.74		1.2		193,332	$	1.74		1.2

Warrant to Purchase Common Stock

A summary of warrant transactions during the nine months ended July 31, 2016 is as follows:

	Warrant Shares		Weighted Average Exercise Price Per Common Share		Aggregate Intrinsic Value

Outstanding at October 31, 2015		750,000	$	0.12	$	—
Issued during the period		153,846	$	0.07
Exercised during the period		—		—
Expired during the period		—		—
Outstanding at July 31, 2016		903,846	$	0.11	$	—
Exercisable at July 31, 2016		673,077	$	0.13	$	—
Exercisable at October 31, 2015		596,154	$	0.13	$	—

As of July 31, 2016, the weighted average remaining contractual life for warrants outstanding was 1.6 years and for warrants exercisable was 1.3 years.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 26 R15.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Jul. 31, 2016

Warrant [Member]

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Schedule of Stock Option Activity

A summary of warrant transactions during the nine months ended July 31, 2016 is as follows:

	Warrant Shares		Weighted Average Exercise Price Per Common Share		Aggregate Intrinsic Value

Outstanding at October 31, 2015		750,000	$	0.12	$	—
Issued during the period		153,846	$	0.07
Exercised during the period		—		—
Expired during the period		—		—
Outstanding at July 31, 2016		903,846	$	0.11	$	—
Exercisable at July 31, 2016		673,077	$	0.13	$	—
Exercisable at October 31, 2015		596,154	$	0.13	$	—

Stock Option [Member]

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Schedule of Stock Option Activity

A summary of stock option transactions for employees and directors under the Equity Incentive Plans during the nine months ended July 31, 2016 is as follows:

	Stock Option Shares			Weighted Average Exercise Price Per Common Share		Aggregate Intrinsic Value
Outstanding at October 31, 2015		203,332		$	1.70	$	—
Granted during the period		—			—
Exercised during the period		—			—
Expired during the period		(10,000	)	$	0.80
Outstanding at July 31, 2016		193,332		$	1.74	$	—
Exercisable at July 31, 2016		193,332		$	1.74	$	—
Exercisable at October 31, 2015		203,332		$	1.70	$	—

Schedule of Stock Options Outstanding and Stock Options Exercisable

Information with respect to stock options outstanding and stock options exercisable as of July 31, 2016 that were granted to employees is as follows:

		Stock Options Outstanding						Stock Options Exercisable
Exercise Price		Number of Shares Available Under Outstanding Stock Options		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)		Number of Shares Available for Purchase Under Outstanding Stock Options		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)

$	1.40		83,332	$	1.40		2.1		83,332	$	1.40		2.1
$	2.00		110,000	$	2.00		0.5		110,000	$	2.00		0.5
			193,332	$	1.74		1.2		193,332	$	1.74		1.2

XML 27 R16.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Details Narrative) - USD ($)	Jul. 31, 2016	Oct. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working capital deficiency	$ 397,079
Accumulated deficit	24,649,593	$ 24,448,728
Principal payment due on convertible debenture	$ 25,000

XML 28 R17.htm IDEA: XBRL DOCUMENT

Amended and Restated SCMS License Agreement (Details Narrative) - Donald D. Hickey [Member] - USD ($)		9 Months Ended
	Feb. 14, 2011	Jul. 31, 2016	Jan. 22, 2016
SCMS License Agreement [Member]
Cash payment to related party	$ 105,000
SCMS License Agreement [Member] \| After Closing Any Single Financing [Member]
Cash payment to related party	50,000
SCMS License Agreement [Member] \| Six Month Period [Member]
Maximum closing single financing amount	3,000,000
SCMS License Agreement [Member] \| After First Commercial Sale of Licensed Technology [Member]
Cash payment to related party	$ 55,000
License Termination Agreement [Member]
Cash payment to related party		$ 105,000
Termination of license agreement			$ 105,000

XML 29 R18.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative)	3 Months Ended		9 Months Ended
Related Party Transactions (Details Narrative)	Jul. 31, 2016 USD ($)	Jul. 31, 2015 USD ($)	Jul. 31, 2016 USD ($) shares	Jul. 31, 2015 USD ($)	Feb. 01, 2007 ft²
Sublease agreement expenses	$ 20,229	$ 19,057	$ 58,464	$ 53,750
Number of shares issued \| shares			7,027,140
Sublease Agreement [Member]
Sublease agreement expenses			$ 5,229
Rent due under the Sublease Agreement			15,000
Other expenses included in accounts payable - related party	23,920		$ 23,920
Century Capital Associates LLC [Member]
Area of office space \| ft²					2,000
Notice period to terminate sublease agreement			60 days
Monthly rental fee			$ 5,000
Sublease agreement expenses			36,899
Rent due under the Sublease Agreement			135,000
Other expenses included in accounts payable - related party	$ 284,865		$ 284,865

XML 30 R19.htm IDEA: XBRL DOCUMENT

Note Payable (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Note Payable (Details Narrative) - USD ($)	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015
Gain on settlement of note payable			$ 105,000
Donald D. Hickey [Member] \| License Agreement [Member]
Cash payment to related party	$ 105,000		105,000
Donald D. Hickey [Member] \| License Termination Agreement [Member]
Payment to related party			$ 105,000

XML 31 R20.htm IDEA: XBRL DOCUMENT

Convertible Debentures (Details Narrative) - USD ($)											3 Months Ended		9 Months Ended
Convertible Debentures (Details Narrative) - USD ($)	Jun. 22, 2016	Mar. 31, 2016	Jan. 04, 2016	Sep. 14, 2015	Feb. 12, 2015	Dec. 12, 2013	Aug. 15, 2012	Jan. 11, 2012	May 20, 2011	Feb. 08, 2007	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015	Oct. 31, 2015
Debt instruments principal amount											$ 25,000		$ 25,000
Convertible debt carrying value net											225,000		225,000		$ 694,791
Loss on conversion of convertible debt													(48,257)
January 2016 Debenture Divided [Member]
Debt instruments conversion into share		787,566
Debt instruments conversion into shares value		$ 50,000
Accrued interest		$ 1,192
Interest expense on debt											0		4,696
Debt discount			$ 3,504
Accreted interest expense			3,504										3,504
Conversion price per share		$ 0.065
February 2007 Debentures [Member]
Debt instruments principal amount											25,000		25,000
Debt instruments conversion into share		856,934						50,000
Debt instruments conversion into shares value		$ 175,000						$ 50,000
Accrued interest		$ 34,302									997		997
Interest expense on debt											504	4,033	7,330	11,968
Convertible debt carrying value net											25,000		25,000
February 2007 Debentures [Member] \| Individual Investors [Member]
Debt instruments principal amount										$ 250,000
Debentures bear interest at rate										8.00%
Debt maturity date										Jan. 31, 2010
Debt initially extended date										Jan. 31, 2012
Debt maturity term										3 years
May 2011 Convertible Debenture [Member]
Debt instruments conversion into share	129,032	128,205
Accrued interest	$ 8,000	$ 16,000									1,630		1,630
Interest expense on debt											2,016	2,017	6,006	5,985
Convertible debt carrying value net											100,000		100,000
May 2011 Convertible Debenture [Member] \| Institutional Investor [Member]
Debt instruments principal amount									$ 100,000
Debentures bear interest at rate									8.00%
Debt maturity date									May 20, 2014
Debt initially extended date									May 20, 2015
Debt instrument new maturity date									Mar. 31, 2017
Debt maturity term									3 years
August 2012 Convertible Debenture [Member]
Debt instruments conversion into share		161,538
Accrued interest		$ 16,000									7,810		7,810
Interest expense on debt											2,016	2,017	6,006	5,985
Convertible debt carrying value net											100,000		100,000
August 2012 Convertible Debenture [Member] \| Institutional Investor [Member]
Debt instruments principal amount							$ 100,000
Debentures bear interest at rate							8.00%
Debt maturity date							Aug. 15, 2015
Debt instrument new maturity date							Mar. 31, 2017
Debt maturity term							3 years
December 2013 Debentures [Member] \| Two Individual Investors [Member]
Debt instruments principal amount						$ 150,000
Debentures bear interest at rate						10.00%
Debt maturity date						Dec. 12, 2014
Debt maturity term						1 year
April 2014 Debentures [Member] \| Two Individual Investors [Member]
Debt instruments principal amount						$ 75,000
Debentures bear interest at rate						10.00%
Debt maturity date						Apr. 01, 2015
December 2013 and April 2014 Convertible Debentures and Warrants [Member]
Debt instruments conversion into share		4,223,392
Debt instruments conversion into shares value		$ 225,000
Accrued interest		$ 49,521
Interest expense on debt											0	5,671	9,269	24,566
Percentage of common stock equal aggregate principal amount						20.00%
Debt discount						$ 36,796
Accreted interest expense						$ 36,796								7,738
Conversion price per share		$ 0.065
Loss on conversion of convertible debt											$ 40,122		$ 40,122
December 2013 and April 2014 Convertible Debentures and Warrants [Member] \| Minimum [Member]
Conversion price per share											$ 0.13		$ 0.13
December 2013 and April 2014 Convertible Debentures and Warrants [Member] \| Maximum [Member]
Conversion price per share											$ 0.065		$ 0.065
February 2015 Convertible Debenture and Warrant [Member]
Debt instruments conversion into share		856,270
Debt instruments conversion into shares value		$ 50,000
Accrued interest		$ 5,658
Interest expense on debt											$ 0	3,178	$ 3,788	5,838
Debt discount					$ 5,983
Accreted interest expense					5,983							$ 1,918	1,705	$ 3,523
Conversion price per share		$ 0.065
Loss on conversion of convertible debt											8,135		8,135
February 2015 Convertible Debenture and Warrant [Member] \| Minimum [Member]
Conversion price per share		0.13
February 2015 Convertible Debenture and Warrant [Member] \| Maximum [Member]
Conversion price per share		$ 0.065
February 2015 Convertible Debenture and Warrant [Member] \| Individual Investors [Member]
Debt instruments principal amount					$ 50,000
Debentures bear interest at rate					10.00%
Debt instrument new maturity date					Feb. 12, 2016
Debt maturity term					1 year
Percentage of common stock equal aggregate principal amount					20.00%
September 2015 Convertible Debentures and Warrants [Member]
Debt instruments conversion into share		405,585
Debt instruments conversion into shares value		$ 25,000
Accrued interest		$ 1,363
Interest expense on debt											$ 0		4,545
Debt discount				$ 4,022
Accreted interest expense				4,022									$ (3,504)
Conversion price per share		$ 0.065
September 2015 Convertible Debentures and Warrants [Member] \| Three Individual Investors [Member]
Debt instruments principal amount				$ 25,000
Debentures bear interest at rate				10.00%
Debt instrument new maturity date				Sep. 14, 2016
Debt maturity term				1 year
Percentage of common stock equal aggregate principal amount				20.00%
January 2016 Debenture and Warrant [Member] \| Individual Investors [Member]
Debt instruments principal amount			$ 50,000
Debentures bear interest at rate			10.00%
Debt instrument new maturity date			Jan. 04, 2017
Debt maturity term			1 year
Percentage of common stock equal aggregate principal amount			20.00%

XML 32 R21.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share (Details Narrative) - shares	9 Months Ended
Net Loss Per Common Share (Details Narrative) - shares	Jul. 31, 2016	Jul. 31, 2015
Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares which were not included in computation of diluted per share	193,332	203,332
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares which were not included in computation of diluted per share	903,846	673,077
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares which were not included in computation of diluted per share	593,750	2,782,051

XML 33 R22.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Narrative)			1 Months Ended	9 Months Ended
Stockholders' Equity (Details Narrative)	Jun. 22, 2016 USD ($) shares	Mar. 31, 2016 USD ($) shares	Dec. 27, 2013 shares	Jul. 31, 2016 USD ($) StockOptionPlans shares	Oct. 31, 2015 shares	May 31, 2007 shares	Jul. 05, 2002 shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of stock option plans \| StockOptionPlans				2
Warrant [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock option plan outstanding				903,846	750,000
Weighted average warrants outstanding contractual life				1 year 7 months 6 days
Weighted average warrants exercisable contractual life				1 year 3 months 18 days
Equity Incentive Plans [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock options vested over period				5 years
Equity Incentive Plans [Member] \| Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock options grant date term				10 years
2002 Equity Incentive Plan [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Aggregate number of common stock shares awarded							200,000
Stock option plan outstanding				110,000
2007 Equity Incentive Plan [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Aggregate number of common stock shares awarded						300,000
Stock option plan outstanding				83,332
Increased in number of common stock shares awarded			814,408
Common stock available for awards under equity incentive plan				731,076
May 2011 Convertible Debenture [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Debt instruments conversion into share	129,032	128,205
Accrued interest \| $	$ 8,000	$ 16,000		$ 1,630

XML 34 R23.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Stock Option Activity (Details)	9 Months Ended
	Jul. 31, 2016 USD ($) $ / shares shares
Warrant [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Option/Warrants Shares, Outstanding Beginning Balance \| shares	750,000
Stock Option/Warrants Shares, Granted/Issued during the period \| shares	153,846
Stock Option/Warrants Shares, Exercised during the period \| shares
Stock Option/Warrants Shares, Expired during the period \| shares
Stock Option/Warrants Shares, Outstanding Ending Balance \| shares	903,846
Stock Option/Warrants Shares, Exercisable at July 31, 2016 \| shares	673,077
Stock Option/Warrants Shares, Exercisable at October 31, 2015 \| shares	596,154
Weighted Average Exercise Price Per Common Share/Warrants, Outstanding Beginning Balance \| $ / shares	$ 0.12
Weighted Average Exercise Price Per Common Share/Warrants, Granted/Issued during the period \| $ / shares	0.07
Weighted Average Exercise Price Per Common Share/Warrants, Exercised during the period \| $ / shares
Weighted Average Exercise Price Per Common Share/Warrants, Expired during the period \| $ / shares
Weighted Average Exercise Price Per Common Share/Warrants Outstanding Ending Balance \| $ / shares	0.11
Weighted Average Exercise Price Per Common Share, Exercisable at July 31, 2016 \| $ / shares	0.13
Weighted Average Exercise Price Per Common Share, Exercisable at October 31, 2015 \| $ / shares	$ 0.13
Aggregate Intrinsic Value, Outstanding Stock Option/Warrants Beginning balance \| $
Aggregate Intrinsic Value Outstanding Stock Option/Warrants, Ending Balance \| $
Aggregate Intrinsic Value, Stock Option/Warrants, Exercisable at July 31, 2016 \| $
Aggregate Intrinsic Value, Stock Option/Warrants, Exercisable at October 31, 2015 \| $
Stock Option [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Option/Warrants Shares, Outstanding Beginning Balance \| shares	203,332
Stock Option/Warrants Shares, Granted/Issued during the period \| shares
Stock Option/Warrants Shares, Exercised during the period \| shares
Stock Option/Warrants Shares, Expired during the period \| shares	(10,000)
Stock Option/Warrants Shares, Outstanding Ending Balance \| shares	193,332
Stock Option/Warrants Shares, Exercisable at July 31, 2016 \| shares	193,332
Stock Option/Warrants Shares, Exercisable at October 31, 2015 \| shares	203,332
Weighted Average Exercise Price Per Common Share/Warrants, Outstanding Beginning Balance \| $ / shares	$ 1.70
Weighted Average Exercise Price Per Common Share/Warrants, Granted/Issued during the period \| $ / shares
Weighted Average Exercise Price Per Common Share/Warrants, Exercised during the period \| $ / shares
Weighted Average Exercise Price Per Common Share/Warrants, Expired during the period \| $ / shares	0.80
Weighted Average Exercise Price Per Common Share/Warrants Outstanding Ending Balance \| $ / shares	1.74
Weighted Average Exercise Price Per Common Share, Exercisable at July 31, 2016 \| $ / shares	1.74
Weighted Average Exercise Price Per Common Share, Exercisable at October 31, 2015 \| $ / shares	$ 1.70
Aggregate Intrinsic Value, Outstanding Stock Option/Warrants Beginning balance \| $
Aggregate Intrinsic Value Outstanding Stock Option/Warrants, Ending Balance \| $
Aggregate Intrinsic Value, Stock Option/Warrants, Exercisable at July 31, 2016 \| $
Aggregate Intrinsic Value, Stock Option/Warrants, Exercisable at October 31, 2015 \| $

XML 35 R24.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Stock Options Outstanding and Stock Options Exercisable (Details) - Stock Option [Member]	9 Months Ended
	Jul. 31, 2015 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Available Under Outstanding Stock \| shares	193,332
Weighted Average Exercise Price Per Common Share	$ 1.74
Weighted Average Remaining Contractual Life (Years)	1 year 2 months 12 days
Number of Shares Available for Purchase Under \| shares	193,332
Weighted Average Exercise Price Per Common Share	$ 1.74
Weighted Average Remaining Contractual Life (Years)	1 year 2 months 12 days
Exercise Price One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price	$ 1.40
Number of Available Under Outstanding Stock \| shares	83,332
Weighted Average Exercise Price Per Common Share	$ 1.40
Weighted Average Remaining Contractual Life (Years)	2 years 1 month 6 days
Number of Shares Available for Purchase Under \| shares	83,332
Weighted Average Exercise Price Per Common Share	$ 1.40
Weighted Average Remaining Contractual Life (Years)	2 years 1 month 6 days
Exercise Price Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price	$ 2.00
Number of Available Under Outstanding Stock \| shares	110,000
Weighted Average Exercise Price Per Common Share	$ 2.00
Weighted Average Remaining Contractual Life (Years)	6 months
Number of Shares Available for Purchase Under \| shares	110,000
Weighted Average Exercise Price Per Common Share	$ 2.00
Weighted Average Remaining Contractual Life (Years)	6 months

EXCEL 36 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( M4+4G[QI0%D@$ #$1 3 6T-O;G1E;G1?5'EP97-= M+GAM;,U8RT[#,!#\E2I7U+@.4!YJ>Z%W!/B\@HD0&#AST0:T\39HS@.?-<*U*KHE5UJ,N2 MYU#H?"U#2NH#-5P$/!DLF/5/3(829"M( ^R?-(TX.0^A,Q98X2H +T7J_$Z MZ^+?(Q_,^39. NJ,8VHF_*>,R-LVH MY;>,./_C6EJ;6$LQMVS#6P1U;VV*8RH95UVMVFB[>M-Z=+%V]#?[KOQ-: _';&OS?M/ M36] 1YJA1Y,X24>&1,QW8OG*\M"_V/Z'D4X$G1H>)%]2-F Q+M*;V"^GH A3&^ M.R6:E((C-Z."N[_8_ )02P,$% @ "U0M2;:A'7%. 0 Q0\ !H !X M;"]?J$.Y6@4A>M&LP%.+-NKMO$8.7\PTVTP;3\F/$_VQOZ[HK\6K+UP%-^*-" M?FT@9#Q(Q8,42] V'K1E"=K%@W8L0?MXT)XE*(L'92Q!AWC0@27H& \ZL@2= MXD$GEB!("1E3GB0*:QZM@> :>+P& FS@$1L(LH'';"#0!AZU@6 ;>-P& F[@ MD1L(NH'';B#P!AZ]%:&WXM%;$7HKIK,V==CFT5L1>BL>O16AM^+16RWT]JUV M6#T'UYG&KUWS;3A9M,#;AT>/ZZ?,4\F&A=9AV@GE?%W]VYJG?H;(7W_LEP]0 M2P,$% @ "U0M2;LX*;EN @ \P< ! !D;V-0&UL MO551;]HP$/XK5E[&'MI05&T2HI$ZZ+1)+44-[9Y=Y])8=>S,9QCLU^_L0!I: MLD$?QI-]_KZ[^^Z.RTAC?SBSI@+K)"!;E4KCD(P74>%<-8QC% 64'$\)HNDU M-[;DCJ[V*39Y+@5,C%B4H%T\Z/<_Q;!RH#/(3JK&:92,?)3+JE)2<">-3FZD ML 9-[MC52H :Q:\!@4&>4Q +*]TZZ=>8MBE@4L$5C"E6DG.%4*->C $S-F7% M]3JN;]=2/^-]-3<3[J#-VGVHO1?<0D9!=[PWQH#YMB:=RG/'!==/D+6Q;Q^W MM7@ BU[IV>"T3[^F!%M[[1MX)O73C$N+R6CIADL0SMA-FY;NO5W*C/!-QX^0(_G@1+;F57+N(H?Q-UT%4AZVMX:PJ=#;Y8>PS%@ .1W%C#,=12OW7!N,[8E78T MCNR[KD-1\]HE:4Y?N.): $M#U5CO7O-%)AUD'P^"DW *6("COXC:3TD=#:Y/ M"YG)V2U-7LAF&^L SIACP;XJ\^N=G)!DAQR4 3ZS@$3MKM-E&19(*.T=H(^5 ML71\D[)K:MY^SAVH //3L69SRS5R$;3OA4^- \*N^:."O8"QT4N_O.B=3>"1 M\EU0VAW%,.+YA.11>+]H@$)W:IN"8]<&DG1I- OKI-MU851&*^$#N_JY MH#$[&,AZ&ULS9--3\,P M#(;_"NJ]2[-*DXBZ'@!Q8A(20R!N(?&VL.9#B:>N_YXLZUH&N^S&K:[]/GX= M)Y5P3%@/S]XZ\*@@W.QU8P(3;IYM$!TC)(@-:!XFL<+$Y,IZS3&&?DT<%UN^ M!C(MBAG1@%QRY.0 S-U S.I*"B8\<+2^QTLQX-W.-PDF!8$&-!@,A$XHR>I7 MLS6V-149]745'3<\X,)*M5(@[[JQ[&\J=D;P.ASE((?VZ>]%#RE#LKYR']10 MU;;MI"U371R8DO?%TTLZFUR9@-P(B*J@&'8.YMFI\UMY_[!\S.II06=Y<9O3 MN;&U]=TS]BLY>5?T-4$L# M!!0 ( M4+4F97)PC$ 8 )PG 3 >&PO=&AE;64O=&AE;64Q+GAM M;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]' M-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D M$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X% M/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1TDB @LE]E 6Z2?:C MTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP' 3@4;N>PIWT;+^D M00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=TXZ)QJW0> V^\4^' MPZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP=M;,T@.67BGZ=90: MV1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,4'RO0;:*X,*2TER0 MUL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CD MGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V& MF&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F M<]%L^P>E1M'V5;SCFED)O816:I^JAS0^ MJ!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$ MKYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"0AMNZ5/U2I77Y:^Y M*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KTL@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9 M!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE T%&UL MK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2 MX]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\, M$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T M74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT M%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ $:MB MOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\4 M8JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 Y3_;U UH]@TT')$% M7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ "U0M2@H T !X;"]S='EL97,N>&ULS59;:]LP%/XK0AFCA1';"4WI:AM&(3#8 MRJ!YZ%N1;=D6Z.+)2_XCZ@OC;47E^@.,P%'^NT@ Z(P_H9;!'5 M_H%Q3P45$BA]$%J#13ABV'G<(4H220R8(T9HY^"% >S9]7Z,<"%M;I?A,,_< M'S/)(HF@W_].3Y>,['8PVR.4[F]/ W%8(:6PY&L] ;V]Z2J].2XX=B*MWPO> MA41=L+B:!-A!YTV$S+ <,@=P!\4AQ;G2 9(4I1F5J(QTH91@VL@(*@1'U%#N M(GI#TZ:8T@?SI3SF>]QM#IR/.6,? J-B9^I"].9X#6Q1O2F;XY[2OHT7M/F0 M0$>CJJ+=)TH*SK 3ZZ"UZ&JO\%>FQ]3^-8M_TU-?[YJHQI]!?]U>?YK\NG9V,\0'N@YX2CN&Y9@ MN;;_S:\7MKP^5V6FL9VMM-7Y2CO; UW>_*8RKV\,D^ZSUWL&%"0-H8KPG01D M7@OW1C;=:PMCW]&<63NV'+NJ4*(?@GM9-%F&<]10]8ULA;*+$1SM+T9^L!J\ M-@-%!$?[*\Y(PVZL@O&U&?\$4$L#!!0 ( M4+4DQ1B/^' , ",) / M >&PO=V]R:V)O;VLN>&ULE95=4^(P%$#_2J8OZSZXT JHC'5F!=UU1I$1 MUGT.;; 9TZ2;I*+^^KU) 2\VKNX3;6E.[\=)[HD9KI1^6"CU0)Y*(1CVX52NV\T#7U5G-A;OI=_M1Q\$VJ4XUR53.&MB\X.;W^H^(Y&Q):V'G M$.SFNVD4)[TD&30,]]H=9RN#@>X!H9GECVQ.%VG4C0BMK;K@PC(]II;]T*JN MN+P'5D267!L[<^GZ-TLN>E,;% "]?YO[#>LCA0E_F<5,J##JC@LJ,$9^!(7N_)*U]L[XB M1H(8R<>,*=406L%\ 3#G '$.VIR9A8ZXK Q12W)3,=V(NXX*@7H(U/L(-**F M(!<@8@#41Z#^_X!\C@@T0*!!J$2&>\94,P.\MUTZ1,L/V\N_0PPYRWVW;V$_ M050YF8VN9^0*]CL&'2'041MTZPX#6 OA@S%S3:5QVP.*C!C'B''<9DR490!X MILY8)%H7F]9MKQLI^>AV!2PC8[: *M10#$S8<34@Z\RJ[&$?:@D9C%0))Y9I MZ8Y=C0.R3N#J2AE#IDP[2 D'V*R ;F((%C4.F@J!%$KD=_:MA_>#WV M,PX*VEY/]N:NH@9OF!C[&0<$#7I%]L;,4BX,P2AL:!Q0])^.Q8<8A6V- [J^ M;YD/#:.PKW% 6"S;:UX3JMW9\+C3-*QM'/ V[-\6BL\[K'(24/E=B1H:1F&G MD_><;JFP312C=H[A@-I!U#Z9P83/ZYV]FF#!DT\*OD4E/8S"KB>]]0A[G5HP MN+EDN9OIQG\&9D+F!CW\-!NVUW>M<_?7,/S3R$UH&,:U$"-X=B.O%/5SK"%O M1OOI7U!+ P04 " +5"U)\4(+54T" #T!P & 'AL+W=O,O>O!S^,ZB'0.I"$'J4-@];B2'6D:'4F1_[J@GTQMO'T?HC^;RS( MCC5_ZJ.L5+91 ([DA"^-?&/]"W$UI#K@@37"_(+#14A&!TL */ZPS[HUS]Y^ M2:"S^0W(&=!H0-FD(7:&>#38I0MM9J:N'UCBLN"L!Z+#^M^&*R7G.HB*#%0Q M0JV3BWX/:(TBLP"K@-$R1HOT,2;S M8C(39#%1AU4L'P-R+R!W64X0G&3&7EEX$0OK]VX6AW"2&;MEZ44LK3^90#C) MC'\"1EZ&F581L@G(H,EG4*"?XAIS\?W.VCD-4ELKR6>QD)]E>Q0NIRIRG1[- MH,1^BFUE!'V4U%&VGY&\41'#IH(?FW[\.:0I82?S>4CP(%=6FG/ MV'%VO. VR!S2G_*RZ/"9_,+\7+<"[)E41[TYD4^,2:(2B)Y4N96Z@L=!0TY2 MO^9Z'>RE9 >2=<,=.U[TY7]02P,$% @ "U0M2>M-I>TC P +0T !@ M !X;"]W;W)KZZ;C^+HG:UTU7>WIN]KNTO&]-4>6@JHP8(3*J\J(. ME_-A[:E9SLVA*XM:/S5!>ZBJO/GWJ$MS7(0T/"T\%]M=UR]$RWETCEL7E:[; MPM1!HS>+\('.,C8@ _&[T,?VXC[HQ;\8\]H__%PO0M)KT*5>=7V*W%[>=*;+ MLL]D=_Z+23_V[ ,O[T_9OP_E6ODO>:LS4_XIUMW.JB5AL-:;_%!VS^;X0V,- M<9]P9K@>X9>48)@[@&$ .P=0X0W@&, _!42@ M;*CK6][ERWECCD&[S_O3IC.+-WT2FSFPQ;2V3T/.9NC4O?5YKA V M((^(C!,9$O$9B>S^3A'L6@0L/C"(E[?C^76\@'@.\#9Y!(2S-'7V#J5@ MHE1>='A4BW2>L(2-R.WXQ%E+ O'44PL@E,5I2CS%($8822>\;ZE338IM\Z@! M1 @J?(>,B:02R81C5DXQ"G)PCQA$A.*^8P:*4D7$A,Y0XE0S+/=[>>0@PUA, MB.^HD!NZ0R=4H7.[5,%S!T34JA8>0K( M/E ATH1-&"N8VU@9F*'PV1@R=UPEQ-NL$TBYI$DR96YS>RM#WW1: DY>R(P. M&3AZ(>::,J*+P7:?;_6OO-D6=1N\F,[.R,,HNS&FTS8-N8_#8&>_7OLF9,H;>N M[>76JY4:-AC+0\TZ*E=\8+W^YYHTWM%;L>> M19'SLVJ;GCT+),]=1\6?'6OYN/5\[SKPTIQJ909PD>-;KFHZULN&]TBPX]9[ M\C=E9@@+_&S8*._:R+CO.7\UG>_5UB-&@;7LH$P%JB\75K*V-87TQ+^GFO^F M-,'[]K7Z5[M:;;^GDI6\_=54JM:RQ$,5.])SJU[X^(U-2XA-P0-OI?U&A[-4 MO+M&/-31-[@VO;V.\$L433%W()@"P2W@+P?"*1#^%\!@9M?UA2I:Y(*/2 [4 M'+:_T;@P171EI!4 "B^P ">:)NT=CJMH4R\X+2>_@Y9&*5^NJ $8!+& M&8D_<3MF3J$,A)(%H>RS0MF"$+Y[8 WTQ'Y0<6IZB?9??40=.5=,UR&K MV$.U?B7=.BT[*M-,=5O 4QHZB@_7=\[MQ5?\!5!+ P04 " +5"U)H[4J M!!\# "%# & 'AL+W=O4A $*O+LK&31,Y]M*F"3OSJFSH2^MTY[HNVG\9K=AEY4)W&/A5'HZ\'_#2 MQ!MUN[*F35>RQFGI?N4^P^4&XAZ1Q.^27KJK>Z=/_I6QM_[AQV[E@CX'6M$M M[T,4XO).U[2J^DABYK\ZZ.>1+7"='=T7 MYXK_8I?O5'L(^H!;5G7RT]F>.\[J0>(Z=?&AKF4CKQ?U#4%:9A8@+4"C8)S' M+,!:@#\%OE7@:X'_Z R!%@1?9O"4=[ER><&+-&G9Q>E.1;^?X%+@;1]$1';$ M MV=PADUX"XUH$R@N:UX?&M0B5'M^FV$@D5&NA$3_R+=1:4RA"\325*PK!( ZC M:6RC,$C"F#RP2XC1&=%I6ZI,YJML1FX\*60!00 L)3Z+M2DH[4&[L%RQ49WL7(76MPI9.$'V$*M-07#&%JP? @&0Q]8 MO&DL\+'_P#L&@=&;'!;F+!LMTXQU,TXP-[XTL_ C9#Y-]&Z\CS7M"II=J=/& MO#6(=@7U5HLQ,6XUHIUICL3$-VYPHMUI3C1;D?E-(-K> &*(T0,'(D1FC^JL M"BVY9YHQ[J)8VU/( CP!.(WE5QB:QC97F/^ ,VQVIDY18MG\F6:06&M((MM+ MI\D0!S$(++]0N08A C$.; :7:V@8S_N.6_9TG^'3Y%0-4Y R>Q)(? MQ7^"\:&B>][?DKX6JDM6#YR=AJ9__.>1_@=02P,$% @ "U0M23Q_B?QE M P = X !@ !X;"]W;W)KPNV,38506I8K78/*U4][)YIXB2H@+/@--U_O\9C\E$Y#I< SGOC-X/]\.1' MV;\/.R%4\-DVW; (=TKMGZ)H6.U$6PV/?PB;@U&XDLU@?H/585"RG2AAT%:?<*T[0?!4-Y M]#'&N8)@ UD"Y(R(='#G##ATT;&AX]L3E("@V?T9R/4,,/A,( =\GY]<\Q/@ M)X:?\FN)G8$P2 (@#WHG\)3>QI43CB""9U2,.O.AD ^YST^=^:203^+2F4(^ M 'E ,8WCV/5J(%0).,+N2V%.*0Q2\4D!"&>(W :5 $((IS.JRIU2.%2%>:0 M).&8,D]-^.R:9,[7FT%-Z'T^BIV9F&&]I9P+UJ8R83")/66U*,+XC,6&D%L- M^ -!/C6 P81EGJ506M@#8FB&&2#LU@-V0K!/#V 000GQ"K(XE/*+.MY61-R* MP*"(9X$O+29A&?:LT'(*Q2F?87?([7<(7(JE/CW6R1)"D7<%65R**4]F*'([ M'K*6-V-/(;?G(7 JYMT3@!DMSYN2"W9;C]OXD'6^S*>'6:/.O'*8W10S*^QV M/P2NQ3TS+2T&HY1ZREA.L!2A.7HRMQYP0>YUCC*[F>FL%NST+@]%PYV%GRL::$8U] M'FI1+$5S\G$[%@:7X3['LIB4LIA\P5U]OBUNSO<;4[<::H\LG@.CQ20T95\/ M8M=JJ%M-='&8;T6_-4W.$*SDH5-PTCZ-GAJI9SPV U_&E[K!@G;H'*;(]]56 M_*KZ;=T-P9M4NM4P'<%&2B6TK/B1AL%.MX"GAT9LU'C+]'T/31$\*+F?>KQ3 MHUG\!U!+ P04 " +5"U)WL#HT>(! #,! & 'AL+W=O-Q-@GYJEH C=XXZ]4>MUH/.T)4V0*GZD$, MT)N=6DA.M5G*AJA! JTTV@9(GI&%5W4<>M6)'DFH]_@0[HK$(AS@9P>3NIDCZ_TDQ*M= M?*_V.+ 6@$&IK0(UPQD*8,P*F<2_9\UK2DN\G5_4O[IJC?L355 (]JNK=&O, M!AA54-.1Z1P%$RY+RI'I06_4##B],V/7>_&R>]L@YFV3HAF0K00 MECSKA,U,V%P)L:O4.W-U?:&:YID4$U(#M3\[W!FXM")&&9EBE#DGIRG=2>79 M.=]N,W*V.G>0R$&.'A(N"&+$5S-$>(T>.7KT[P2%1R1/GV?8W&?PP'WM^[/A/P;W%WD$>?1$>DB;Q-HE62_%2A<=MTL^M)*M6$F\E_,"*AZ1! ME(9Q\(&59-T*N;DE'&3CND>A4HR]]K]PB2X->HCL+7L7/YK&]7UVE&PO=V]R:W-H965T&ULA5/;3N,P$/T5RQ^ TS0LNU4:B8)6NP](B(?=9S>9)!:V)]A. M W^/+VEH404O\%+=7.(#V?UHT MBCN?FH[9P0!O(DE)EF?9#Z:XT+0J8^W15"6.3@H-CX;842ENWG8@<=K2%3T6 MGD37NU!@5-\C/H?D;[.E6; M$FH7%+A?#G '4@8AW_AEUOQH&8BG\5']=YS6N]]S"W\+I#\PC7 ?!&J6-7U*/UJ$Z4BA1_#6M0L=U2G]^9C/M,B&?"?DG DN-HLU[ M[GA5&IR('7@XN]7&PTT0\[-^[*AIXN!5>:A^Y24[!)TS2.+M$F2U()@7 MO]@AIY?H>:3GW]/7Y_1U,KA.!M??\XMS?I'XQ1<#)LANAA2?6K"3_51@NGAM M+*EQU"YMYU)=;N9M'L_C UZ5 ^_@@9M.:$OVZ/RIQLUO$1WX[MG5-26]?SM+ M(J%U(;SQL4G7*24.A^/C6%YH]0Y02P,$% @ "U0M25AAHX"C 0 K0, M !@ !X;"]W;W)KP)$W M);7=T=ZY8#+&C4MR\[T'BM*,K>BH\BZYWH<"JDBV\1BC05J F!MH=?5AM]T5 M1, ? 9,]BTGP?D!\#S8 $DU"XH<+\&TLJ7'4+FWG4EUNYD,>S^,37I4#[^ W M-YW0EAS0^5.-F]\B.O#=LYL-);U_.TLBH74AO/.Q2=6CG-"\VA[ D3U#EN'G?@L1I0W-Z++R( MKG>AP*J2S;Q&*-!6H"8&V@V]S]?;94!$P%\!DSV)2?"^0WP-R5.SH5FP !)J M%Q2X7_;P %(&(=_X_T'SLV4@GL9']=]Q6N]^QRT\H/PG&M=[LQDE#;1\E.X% MIT\*@U.Q X\G%V^]G 31+PR\=ZL'SMJFCAX5>ZKNU7)]D'G#))XVP3)9P3S MXA<[%/02O8CTXCI]<4Y?)(.+9/#N.G]YSE\F_O*; 1-DFR!YEGWIP4XV5('I MXKVQI,91N[2?%4.O(,_W'1"6[)#YX\U[GZ+Z,"WSVYN*>G] MXYD3":T+X4\?FW2?4N)P.+Z.^8E6'U!+ P04 " +5"U)QGX&P*,! "Q M P &0 'AL+W=OQ-W5S.PL'^6$YMWV M (Y\**GMGO;.#3O&;-V#XO8&!]#^3XM&<>=3TS$[&.!-)"G)BBR[8XH+3:LR MUEY-5>+HI-#P:H@=E>+FUP$D3GN:TZ7P)KK>A0*K2K;R&J% 6X&:&&CW]"'? M';8!$0'?!4SV+";!^Q'Q/20OS9YFP0)(J%U0X'XYP2-(&81\XY^SYF?+0#R/ M%_6G.*UW?^06'E'^$(WKO=F,D@9:/DKWAM,SS"/T)4=T_F3C ;2(#GS[[.:6DMZ_GS61T+H0WOO8I"N5$H?#\D#65UK] M!E!+ P04 " +5"U)I,QA&:,! "Q P &0 'AL+W=OQ-W5S.PL'^6$YM7V (Z\*ZGM@?;.#7O&;-V#XO8.!]#^ M3XM&<>=3TS$[&.!-)"G)\BS[Q!07FE9EK#V;JL312:'AV1 [*L7-KR-(G YT M0Y?"B^AZ%PJL*MG*:X0";05J8J ]T(?-_E@$1 3\$##9BY@$[R?$UY!\:PXT M"Q9 0NV" O?+&1Y!RB#D&[_-FA\M _$R7M2_Q&F]^Q.W\(CRIVA<[\UFE#30 M\E&Z%YR^PCS"+@C6*&W\DGJT#M5"H43Q][0*'=K!\[:IHX>%6>JTU6E.P?6;+7)ZBYY'>OYO^O::ODT.M[/#_Q HK@6*)%#\;<2$.2Z8W1]-V,6> M*C!=O#J6U#AJE[9TK:ZW\R&/9_(!K\J!=_"=FTYH2T[H_,G& V@1'?CVV=V. MDMZ_GS61T+H0WOO8I"N5$H?#\D#65UK]!E!+ P04 " +5"U)3SX$RZ,! M "Q P &0 'AL+W=OP)%W);4]T-ZY8<^8K7M0W-[A -K_:=$H[GQJ.F8' [R))"59GF4/3'&A M:57&VHNI2AR=%!I>#+&C4MS\.8+$Z4 W="F\BJYWH<"JDJV\1BC05J F!MH# M?=KLCT5 1,!/ 9.]B$GP?D)\"\GWYD"S8 $DU"XH<+^]9\Z-E M(%[&B_K7.*UW?^(6GE'^$HWKO=F,D@9:/DKWBM,WF$>X#X(U2AN_I!ZM0[50 M*%'\/:U"QW5*?W;%3+M-R&="OA(>LV@\-8HVOW#'J]+@1.S P]EM]AYN@HA7 M)MZ;]6-'31,'K\ISM2G8.0E>81#S.F!7!O/K-%CF]1<\C/?^QP][E <2U0)('B?R,FS''!//[3A%WLJ0+3Q:MC28VC=FE+U^IZ.Y_R>"8? M\*H<> <_N.F$MN2$SI]L/( 6T8%OG]W=4]+[][,F$EH7PIV/3;I2*7$X+ ]D M?:757U!+ P04 " +5"U)(&S*E:,! "Q P &0 'AL+W=O1=>[$&!5R19>(Q1H*U 3 ^V6WN>;W3H@(N"W@,F>V"34OD=\#\ZO M9DNS4 )(J%U0X'X[P -(&81\XH]9\RME()[:1_6GV*VO?L\M/*!\$XWK?;$9 M)0VT?)3N%:>?,+=P'01KE#:NI!ZM0W6D4*+X9]J%CON43E;93+M,*&9"L1!^ M1 )+B6*9C]SQJC0X$3OP,+M\X^$FB'AEXFNSONVH:6+C57FH\NRN9(<@=(9) MQ-V,61#,JU],4=!+]"+2B^_IJW/Z*E6X2MGS['N!];G .@FL_]=BPNQF3/YO MD^SD3A68+CX=2VHG9]L'$"+Z,"G MSZZN*>G]_UD<":T+YJVW37I2R7$X'#_(\DNKOU!+ P04 " +5"U)JDFU MBZ(! "Q P &0 'AL+W=O&<,V=\ MJ68T+W8 <.1526T/='!NW#-FFP$4MWY '_+]L0R("/@E8+87,0G>3X@O(?G1'F@6+("$Q@4%[I.7-)-U MJ%8*)8J_IE7HN,[I3Y$OM-N$8B$4&^%+%HVG1M'F5^YX71F5Y4[!R$KC")>%PP&X)Y]9LM"GJ+7D1Z\3%]=TW? M)8>[Q>'N8X'R6J!, N7_1DR8XXHIWS5A%WNJP/3QZEC2X*1=VM*MNMW.AR*> MR1N\KD;>PT]N>J$M.:'S)QL/H$-TX-MG=_>4#/[];(F$SH7PLX]-NE(I<3BN M#V1[I?4_4$L#!!0 ( M4+4D4H^'$U $ #X% 9 >&PO=V]R:W-H M965T\,+9+O@ZZ85\5Q6 1A^<->J(*ZW; R$JJX!3]2!: M:,R;0DA.M5G*DJA6 LT=B3,2!<&&<%HW.$W#CM+<(!?M?0JZLYLMG/0KS; MQ<_\B ,; 1ADVBI0,US@"1BS0L;X[Z#Y:6F)U_-1_=E5:]*?J8(GP?[4N:Y, MV "C' K:,?TF^A<82HBM8":8+=-7M_2U3[@:$FZ6!=:W BLOL!X$MLL"\6R">!#8 MS7TCCSF-F/VRR6;69.,%HF!98#M;YO;^,G>S"79WE#E@HCL.PW[69#\(1-^8 MC)C5%Q-R=< YR-+UL4*9Z!KMS_>T.UT5CY%KD$]XFK2TA%]4EG6CT%EHTV:N M&PHA-!C[X"'&J#*7V;1@4&@[W9JY]/WM%UJTXVTU79GI?U!+ P04 " + M5"U))$,@],P! "&! &0 'AL+W=O<[Q]@N1JE>=0M@T)O@O=Y%K3'#%F-]:$$P_2 'Z.U*(Y5@Q@[5$>M! :L] M27"<$++"@G5]5!9^[EF5A3P9WO7PK) ^"<'4GR?@[R+B+ "'@W$*S#9G MJ(!S)V0+_YXT_Y5TQ.O^K/[5I[7N]TQ#)?FOKC:M-4LB5$/#3MR\R/$;3!&\ MPX/DVG_1X:2-%#,E0H*]A;;K?3N&E369:,N$9"(D%T),/R6D$R%]1\#!F<_U MA1E6%DJ.2 _,_>QX:^'*B5AE9,-HNT]>4_F=*HMS&2>TP&&GOZ_"%II#1@57I*?\"4$L#!!0 ( M4+4EUKNM<"@( /@& 9 >&PO=V]R M:W-H965TBX^946I E\-:^4JJI3JEA#* M744;(I]X1UM]Y\!%0Y0>BB.4G:!D;TT-@S%",]B0NHW*PLZ]B[+@)\7JEKX+ M($]-0\3?%\IXOXIP-$Q\U,=*F0E8%O#BV]<-;67-6R#H814]X^4&QT9B%;]J MVLNK/C#AMYQ_FL';?A4ADX$RNE,&071SIFO*F"'IRG\\]']-8[SN#_0?=KDZ M_I9(NN;L=[U7E4Z+(K"G!W)BZH/WK]2O(3/ '6?27L'N)!5O!DL$&O+EVKJU M;>_NS)&WA0VQ-\07 TX?&A)O2*8:4F](OQF@6XI]$!NB2%D(W@/9$?-YX*66 M"P/19*!7+_6#M4QA'VU9G$L)Q0!8$9(^" MSEQ0IS$Q)^2$_"@^_5'Z_U&80A4K!JRVG(T?Z MDXACW4JPY4KO7G:3.7"NJ.:@IRP"E3Z&+@-&#\IT<]T7;F-V \6[X9RY'';E M/U!+ P04 " +5"U)7M"&O[D" !U"@ &0 'AL+W=OD)HZ( @E04.KUB\+,_?3U!-!600#;U\UK!45;[V.'9;^(UYL<:PA!O&[8E=Q\^[I MX%\Y?].#G_NECW0,K&8[J26H>KRS-:MKK:2<_X+HIZWMVH)=:OO#K#P8YF AWO!;FU]M=A.1-3_&]AG[89]6:Y]7^ MDR"@N0D$"&0@$#Q)"($0SB5$0(@^">DD(09"/-J-R!>*'BG192RI^HKU-(9SU=WWM$1Q>/6C&^86)VP=.C)A,E!Y \_8!=A\L>/)D@0T'H##)\AD;&[N_ M=!S-V-H]*)R9E/M;Q_'4]H;C$D DB[(DGJJR$V=#"FZNR(9U1]/-"&_'+ZVT M1_DP.W1,CT1?L=_F5WBQQH[Y#5X\V7[H4[XLSO3(?M'N6+7">^527>SF_CUP M+ID*&3VH#N"D>L!A4+.#U*^I>N]L5V0'DI_[)F_H-,O_4$L#!!0 ( M4 M+4GLV'I@( ( *(& 9 >&PO=V]R:W-H965T1% 'AG#XN^"4#[,HR0Z!U[;0Z-, -85 M''F[EI%.MKP#@NSGT6,R6Y<&80&_6C+(JW=@O&\X?S.3'[MY%!L+A)*M,@I8 M#R>R))0:(9WXC]>\I#3$Z_>S^I.M5KO?8$F6G/YN=ZK19N,([,@>'ZEZY<,S M\24@([CE5-HGV!ZEXNQ,B0##[VYL.SL.[DM1>EJ8D'I".A+&/&%"Y@G9A9#? M).2>D/]O!N0)Z%,&Z&JW*[?""M>5X .0/3:_4S+3<&%$M#+0RR7U3EA-8?>B MKDYU@K(*GHS0!TQJ,0N'0=^F(2LO,R*@-A!TD4:A#*FEI],)E@Z!OM_P<%=D M_45DTF;VT6;N%BNS_"(/I7"0A8-DY31D&89T%E*Z4APDB5$Y\$6W[LE/NGQNC87A]3.\Y5T0[CA]TR8V^,,8))7ME7DNS%JZ'NHGB_?E&&*^E M^A]02P,$% @ "U0M2?^M_$.%" JC@ !D !X;"]W;W)K&ULE9O;4ALY$$!_Q>7W8-TO*:!JP1A"N%4>=I\=&((KMH>U MG9#]^_5XNL<06CV=EX#)T6TD';4T\N%+O?J^?JJJS>#78KY<'PV?-IOGCZ/1 M^OZI6DS7!_5SM=S^SV.]6DPWVX^K;Z/U\ZJ:/NP2+>8CHU08+::SY?#XW MN]7Q8?UC,Y\MJ[O58/UCL9BN_CNIYO7+T5 /\0]?9M^>-LT?1L>'HR[=PVQ1 M+=>S>CE858]'P[_TQSNM5^#IO9?Z_I[\^'3P]%0-96HYM7] MILECNOWQLSJMYO,FJVW1_T*N^T*;A*]_Q]PGN_9NZ_]UNJY.Z_D_LX?-T[:Z M:CAXJ!ZG/^:;+_7+106-\$V&]_5\O?MWW$2['8= M?DLR:B?);HJ-IYOI\>&J?AFLGZ>->?3'AE\U^6PS'VPGUGH[9W?9KG:S]OCP MY['V\7#TL\GI#6-VS DRJ\@WO9G<]F=R!YGL&SW:CBAZ6)FWP\JU MP\I =.J%OG@DJ%%T.9T^RZG46CP&R7CE)29HN M":0;F:$_!NA-2>\;3E%,?6@I:K!B)*V88"%M(76@@D2_FC:>!N7%+,F#UH]V MG,1AS #4ITT28VI$ZT-[P>P'*/F0+=.EGX"3SEY-^T@'@2@V04Y;L$JQS2T5KF6%[ MJSOSOIH$3-MH]^HLB#\ ZIU(%,9$9[2##3@XB?*@[6HTIX=VF'TV>E]=45F% MVM(^M*@Z1KR7"(DV7);VH04?9K9%"$F6$DM+T\9^ MPU]VD,3PEC:A!>-DT:2DA6-1.)RY$0K:6TE]'2T ASM-+A!&J,?)@,6D.4M0 M%%-MVA$.MZV8D]_M,3)#L\-14YVM+L7-IA#@S%.ON@@B<$<;3"'$1UCL N$1)L_1QO, MQ7Y57G201)6.-IA+_:J\Z""1>FC-.3!8EN3A:7UYU3^FSA&2;K \[1RO^\?4 M.4)9$N%[6@#>](^IE11$3VJ?( ^)&#P]7[TD+ '(&6.M M*#(,],0.&)=P9X8 &>E)3Z G=L!@@HN! '+9&]&;&7IJ!SS>YN(6@)AE_1H0 M'Z(N4S= 9<.%$K= &2=[%11HEP34!+-G..\@44&T2P*^\F/>C9P#9$,412R! M5D[ LW0R,L2B/%$4\93!3%$4K8?"FST\).?>C@ D?3L2:#4%/&9B#FNN ')* M&U(*\'Z:Q)@:T0X+Z#!)%!5HAX7,/< ,K8*7? >:E$^&1A$4\P*5UEP$@RG) MH(BTOJ+N'Q17 +T=%.^P&Q)C:D1;+F)L(ED:(^V3B&_GN-4&H.2#B9(%(-)* MB:@4]D5V"TF#R$@K):)2N+4&(!^\:%C0KHC="S5F @/$+36 V,+X@BF.5$S, MF]!;H'P223 6;AV@F9@%8 +0=B:S,G Q. WI3TKC[7F%76S/.Y MZ0K\?15]G=4V@N;#;/+^%%!=$:D6@3)@B:M"3N3+3ADA/T-D#BWJ8- MESQ45[+4)]I=*?3O]2;ISVX")-HF";=@S%YO@I!HKY<*EYC0 ,Q>;P*0D8T7 M>F:GW+^KGZ3N392@H$S/ZXS!"Q/R3SI($H=G>L)FG+"2W6NF)VS&"9XQ(26^_:8*]QF5X)3VK*-$0M>J<%=1F7ZE MGR%EM.Q":.&RHA*^KW,39Z]4V>Y^FWZGJZ^C9;K@=?Z\VF7APU7]UYK.M-MK-IOTK4?-O7S$7PSL/MZXO'_4$L#!!0 ( M4 M+4E2D'4^* ( +(& 9 >&PO=V]R:W-H965T;W8=-)O.P^URU"IF6LFV5V7^__4#421UYH>WE MG'//O83;LA?R7=64:O#!6:N64:UUMXACM:LI)^I%=+0U;PY"+N_J']WY1K[6Z+H1K _S5[7QBV,P)X>R(GI-]'_ MH$,-J17<":;<$^Q.2@M^H42 DP^_-JU;>_]F#@=:F( ' AX)8YXP(1D(R94P MDZ597G"J.BC,]6Z Z# M'6;M,6A$Q$8]F )'(3KV*1XGV'A$6CS/D-QGF/DB$F\0P^<"LWL!'US-O,4I M FG003H(H/LJ6X?)?!\\!A5)DN#'L,T@!>]@#^UD03N93X6RYP)YL"'Y](;, M@P[F$QKB,05,YK/LBX9X6)8G,,^?VRF"=HK!SH2.(ACLB M/; E"01,(36C* M $J+)$_A%UVYB.5S#-//_V9\,PHXE4FU:!K=!F4+EY^I'J M#UITEQMBO*:J_U!+ P04 " +5"U)=*,HKQP# !'#@ &0 'AL+W=O MCJK=XJU7@?15[6=_ZV M:7:W05 OMZI(ZQN]4Z7Y9:VK(FW,9;4)ZEVETE4G*O( PC .BC0K_=FTN_=2 MS:9ZW^19J5XJK]X715K]O5>Y/MSYS+"&;38-"MLD*5=:9+KU+K M._\;NUV ;)&.^)6I0WUT[K7%OVK]UEY\7]WY85N#RM6R:4.DYO"NYBK/VT@F M\Q\,^IFS%1Z?V^A/7;NF_->T5G.=_\Y6S=94&_K>2JW3?=[\U(>%PAZB-N!2 MYW7WWUONZT875N)[1?K1'[.R.Q[Z7V2(,EH *(!! ,FH@*. NPH$"L2G8+RD M" 71(!!\5!"C(';-D* @&01L,BJ0*)#_90CZZ>@F\R%MTMFTT@>OWJ7M$F>W M!J_:(":R9V:P-HNCBUEURV,V?9\!\&GPW@8Z8:!C[BTCSC-SRT3GF0?+Q.>9 M1\LDYYDGR\CSS+-E)N>9!3(\')C C!LY>' Z>+P?/.@",)9<#L!/ X@^ ,<* MV&F592*[YE'RXC+22291&( T@Z8Q#(.,S,ADTPP@,/,L)"@;$3GL M^[1OX K? .T;8)?']ADA[CBV0%L'P&%L$9*<!1['+ O+VW!T=OO+MVH M'VFUR]6->9'NWG?76C?*1 EOS#O]UGS5#1>Y6C?M:6+.J_X[I[]H],Y^ MM@W?CK-_4$L#!!0 ( M4+4G",Z=;CP, -$2 9 >&PO=V]R:W-H M965TVH,Q+GBKRKJ]#P_.'>^B MJ-T<3)6W"WLT=?>?G6VJW'6WS3YJCXW)MT.CJHP$8SJJ\J(.5\OAV5.S6MJ3 M*XO:/#5!>ZJJO/FW-J4]WX<\'!_\*O8'US^(5LOHTFY;5*9N"UL'C=G=AP_\ M;JU$+QD4OPMS;J^N@[[SS]:^]#<_MO\?WG\KI,W?9&NV&/=1LAH&OEJ\KH;)E]-H7FFA\P[77$LBZJJC M"!%BS85'Q.SC G):0/D^2L_G^N,":EI ^@(*"B0?%XC1'L0P!#Z=I7K0:#], MKTEBUGT^YFB4HX$C9CA>PV.9*L*$)"@G 8[$WKK7K+U&$N8L11DI,-0,(R4S M,I21 2.>F2^OR1AMOCA#0?T&IN#::? >%>P<$L=#SWCC+R.Q*X4PAP"JUG," B87"7$. 2.IG#<#H& M=P@!#J'3.8R@8W!_$!#Q@I"< L]X\8F0%_@N%I28'T5,2DDP1('O9'$CZ:?S MJNGSBF]C00EZ04]Z@>]A<2/KIQ/G15\X[0>2P'>QH$0^B'A&>T<2W\F2DOD@ M(J/PW2PIF3^*B"M/XCM:4C(?1'Q!6!/RQH_V&Y$_67H@HBP]B0>\I 2\I >\ MQ*U!W@CX:1Z"BBU2 @@W!DF*>%!U[X?PXT_BWB!)$0\J(@FW!TF)>!#1EASN M#9*2$*>\ KW!45)>$5/>(5[@J(DO*(GO,+]0%$27MU(^.CJR*$RS7XX66F# MC3W5SI\X7)Y>3F\>AL.;Z%V^6A[SO?F9-_NB;H-GZYRMAO.)G;7.='BVB,/@ M8/+MY:8T.]=?)MUUXT]<_(VSQ_$ Z7**M?H/4$L#!!0 ( M4+4EQTY1' MLP( '4, 9 >&PO=V]R:W-H965TU9-+4^F:P?QK")]ZGNN_JQ%)\^KF,33PDN[/YAQ(6GJ M9([;MKT8="N'2(G=*GXD#VO*1HA#_&S%67\ZC\;D7Z5\&R^^;U=Q.N8@.K$Q M(P6WAW?Q)+IN9++*OP/I/\TQ\//YQ/[5E6O3?^5:/,GN5[LU!YMM&D=;L>.G MSKS(\S<1:LA'PHWLM/N/-B=M9#^%Q%'//_RQ'=SQ[.^4:0B# V@(H'- Y@(2 M+^32_,(-;VHESY$^\O'AD0<+5R.)98YL;MJ6[3B5*[RIWQM:5'7R/A)=8'S@ MVF/(C$@L.RA!8RB<>@F6WB;(+@DRGV/F]0F[3;"\)%AZ@F7(@%P6.3A,X;/T M&%)E649OZ^2@3AYT**13>1V/(0NVO*U2@"I%4,F@1^8QZPF#$&&@" L$^966 ML;M:5H(Z):)EY1TMJT"5"M&R"M\RDH(J;GFD*! 4!-SJA.#W.J%P%I/?V)66 M!A!98*K-8)T,X:H *G%;A,#V)4O$)@D@7$6P?4F.V"8SJ$3HP 8F!<)< 83M M'.QBPC"=8W=T#G8Q*3&=*^_H'.QC,IFT0KR,4M!A-,4[C!(P"TJN.8R%MUX M(51@'U.*\%< $9+:'T(*MC+-KFV3J: ,71!L8[I$;)()5&*J@6U,QPZF;(G91&6/UTD=V)GQE-ESY:=B?V'D M<1KRYR^-YB]02P,$% @ "U0M2613%'$%(P TJ< !0 !X;"]S:&%R M9613=')I;F=S+GAM;.T]VV[C1I;/J:\H!!ZL&V"K=9>=R01P[.[9GNV+I]U) M,!CL RV5)$Y3I$)2=GN0KY@$N_^QG]!?MN>K9LWR^%ILP[Z5;D<"799IMP@+^S%;/\FTF MPD6^%J+8Q,^&_?[TV2:,DB_Y+HE^W(GS=)<4?_IR>#+X\INO\^B;KXMO+M+Y M;B.2@H?)@C]/BJBXXR\3.6:4)OPIS]=A)O*OGQ7??/T,^\A^I_QUFA3K'/HL MQ*+^]2^[N,='@X /^X-I_>.5V/9X_]3]T"=645YD(?1[$VY$ M8\;SE]^?O7E_QE\_OWAY?O:*G[]]=^D9ZAPFS\(8)EV(C_P_Q)T7PO=WV\9, M@_[3OWH[7(HL2G%5"WX1%HV^&FGLBR]6=_^A1@'PT\6'D1Q2+CY]!OE68-E%QMPAB_OQ/;-"NB9,7/ MT\TV3!H--8[3S09XZZI(YQ\"?D4,QM_NBKP +H3N]6[OLQ!_YE=WF^LT;E+W M^]=>G*NE*]2_@)\;K/S7T;[>A#AGWV_#.$SF M8 (I?SX^^2<+>("K%X I+S MW=4%/SYZ4N_S=EX8X9CX2!;F.0SX5>-SF*_KOUUF8AM&"RX^@D+(FZ+Z/BU@ M#?/*P"3N!7V0/_C@B*/P.HJC(A)-8,[FZ ]ME.^!=RGB8W O@+AUJ(:P!OY]!,U>5:\-<;ODD+X0$=->Y7^3:< MBS]]"2HU%]F-^/(;[IZJ90ID]*A 5FI\(N9?I_%"9/F_P7*6T3P2R?RN@64@ M[U+ 8A8\E_)RU.OW!XA!?A/&._%'X*.@WZ?_*67-PUVQ3K/HGV+Q1YZD^M"8W68G64JBL'#3*/=@>R]%"?*NO>O: MX#)$'ER+(@(M@AKAB#_SV-.K A9!.B==@MI)8)P(]5::$RKXW\^NT<#-B__< MRQ^&>/661QR)N[=_@\I=>W3A+R]PU69[87 V[P* :IKZK8TA18ZT>+L5&;D> M';7[J+-CU-#]+Y-YN@'N,:S@)_H[<2.2)A(5L& JM0YMJ),_BT2@?X-\'2XV M44*.$PIBHR5XCAP1)XHB-KR9^+7F-Z_2/.?++-WPU&"MN;1G)"QB.)=T:38#R):K5&_ MA ! N!(\V6VN81@"JAPIKZJWO<-6F0S-.KAUZ6U')J/V2VIOHQOH'J).]9CK MQ3]VN31&8/I! P-2Y^#7\42C!W[%?\]Q]%T.:T8&Z#0T6&Y!>@H6$VD*PY_= MZ':^#I,5RF]ENM)1:7-"WG0!>!_^EE+AMB_R,DOG0BQ4%]0UI.Q]W.F0;@C. M/% M3G1GY>KT_>$L&(S[+=-7E6MXH,?LUR(-UZ.#VV'U]UL>VYK6G;P2F\@HCX'. M]MD0>1;VYC >VJP&%EMQ^"VH:D+?)3KZ("2N/,/;;!4FT3_I6P#Q:Y*G<;20 M*1)2%"U]U_ALV&XV Z/@TFIR-<'_P";M>=R4++? MV4-[F=4(!2N% L8FN@(1X]T"J0.XM#T@I,T&?3M%+LF>" 5 0R8.%ERL 8>[ M1&F6XJ['WR;\37HCR <<])&C^M.@(F!Q-$?'=L'P1_$1IL]1$("UX\73VPA@ MR7!:PFC78"R#L$F=#Z4[0 M)88_ %B2>%HMK$$CG(>K3 B=S*Z)(JR$$ BXO#/V . V@ZQ%O-!RJ, *%/-( MX2A$'(-GL@O+@0)^BY/DJ!=5D@/O@5\2D>=,,0>M"-APB0E(&%D);D"Z=^0D2)61PM"9S6K,9C6,WPL !VUIED* MAHX'$+(:,@>/P-BYKOYVH8NER;G6BA!7N%Z=ENU#+?(DY(1A,%2064"QLPD MW98[S,O49ZJJ3JTWE(P9A::$V_E-:[T/::6,/ZZHX(IBE47R5[K)*QK?GW(E3^OZ=()=C(8W(*V6) MSK0E\G4]JW2=;_+]78>@7;M/C#;WA;C.R.@.QEK=V+03%)$M&)BV%+UIY^CO MM?:_<\Q!5@?@RV]!9L(XU5Y+.0/Y+A=(Z06_Z/%_C^8?!)CDUSWXX_C3 MS_)O:$0+.H]!?I_WV"OH#? GV$+_&]I(C5&.':CAJ*_I RI"&S+R!6CW@IML M.*!1^BS:%X,IE/G_]$N/X0P'XSC L9:[C.0E5+T!8Z$W8JPHP %<3\<@IEQ M 2!^B8H$8SGE!SDFAY^9<6%6N,&N'"_-1+^2C\NJ/BZP/$B#- M6 N=HT)>Q MVVU8!O]5GPX!TJ1%ERK&R/0K\#>?\*-)WW16EDZU3!.&?IE8HNH*^0*Y6NI, MA"="E_)XU'\"'^[ U)##2J$6Q,,J>T=& /X=V_Y,#3)L!HI.A.!2'(W,IAM) MR1THURR2YLD,D-='0'E$JL-4'_GQ] EZY2"A,BTHMWLI)]>A]&FD?:NARP.435&D]9M1,%.7I0<748CB,V7B3&;@70O'%K!N>@: MTE4DQ' ASHC)&7I5)I)&H8RC*H&;\D:VE&?*$1+'>*PV7L-^OU-]+C$=R-^# M5LN5T]2]94LR;]3C+?TN0O!Z^;L>?Q5^C\Y7!8/HHY^OPP@#YX R@=%"%V>= MKR.QY,\_@I-%L<1;Z?H&]/'].MV P()6_'.$KMJB/JS5\7OH5HX=J(%-QI*I M@6G<*]RJ0&T,TV2BS(G)?#,EON[XN4K6G>5Y"B,4P*ZO7IVCA:VU(!$IHZ'2 M/PG8L-^?-7,"]1FJ0HP>'$F4)W;=31?,WO"3.71%*LDA*M\AX8/U&X,;'8T[ ?#H4PW'TU.@O%T7*U<:6I+Q%NN M'=DF%Y+E.@,QBMFH[YJ=MMF.!B.IO&&<3,O_T6@:G)R>XF]Z7;6:KK.#=_ 3FUL 047PTUO15#5' TF")1EN94#; MO]S1DDJ8-HCD#D)CK^O3?U6W MNYHBP9PB44'0Q"\2 RSOFBF1& 4S<)KO(Q(E!AKFF=R22W>%R06F2B[*/6R_ M%1[WN#U0AV"'A=T""N-%^2.H%E^IZ0U:F&;&';1VC3*QPJ0ZD-""K.+CN?PZ MS#)C 2;U1+)HD?13GC75D=F:#\O95JHNB-(PE>UK&MZJ#VJ0UJ[@O/!N^DYZ MW-VP]!C07? ULC,?)[1!4_,LY 8R._F#9Q,ZH,AFP:LJ$D>)5.I]M4*B%,+> MXR8)):89JD 2/)]K 64Z8C*:JT57F,]LME0!YL> M2PJ"WY;LE.9H)3",2!%7%O1VZQ2K-XAT.@9 8,O!NI(=(RJ%)ZH*_U MSVVH4]HXD/A82,Z!%=9Z#"NQV4#]Z,3_I%)4ZJB-6.[BN"*-J@=:H;+8RJ(! M;K&J1((/=P0>)4^8V_RKZH*3R10+6P^!;C";M(.G]H\+B[1UVBM+/PY&_:$J M",ET_>PN(>? T-UO8[VV76:-],+YL:*30849TX,^Z4'>JBUS)3W:'_>@RB2K M]"2*N\LZ.MF1-:M(E$JI8I",46AMA$DP*!J$EG/:)E;[A5I@O9*D8W0)##/ M.$I:%#"5.A:$91[&DZ@LF]FD[ !NFUOF!'<<]$0%W.Y+D[(P MKG(TI$4,&M@A5VGHTLW,J9L[,&P#/GWJ24AM,;&?2--Q)B675>1,5.[9!IGT2[) 9, YIQ1O2GDH')#-.G)O%0)PW\A;.[EL,: C3W<#"%L.DL0G)Y,#H&- M6;"Y#U85.B.)=;56/_5]:D.D@F(Q.]E@0 M-X8>T8BP*@*M#*WZ?:Q-28OZ?4#HQ!ZF?IWX^>UHX"[@'9ZB?30E+,%C=?#< M>G@6G R\>MC-I]U5,7L,O_\05>P$^![:^$+,97TX"0\N4FH2\F8M]-28MJR+>JZ@Y6@S16SW^A;D@0=EUS)R;ZTCZ>5 MNY;VYI0"0F4N?@=2,+4=0#@;33$<*T3YQY#0)"WW4D@Y138/9:9GJM:!%?T8N MVGQU01P6LFP/MWATL4V3BR5>]6Q4XVS T$9 %%+K-XS2+M=;EL*X8Z;1!L08 M')84= B3,.K\%G+K4\.M#H)T]<3&P7 X"D:G0X\O%B!#'?5[_>F$.$F=)G=L M"\CLDS/]5./[(SRR-AS4TOZLGO:W#):]K@M3FP_XP)JZB [1NS/DM,T(X(. M&NCIS(TJRC>^5#G#$Z1T<\4>AHO5*7[I]MDG^6LL1RG+?C 8#F%A9I_:[?JP M\@3?YW#F^I(*I\%P>GJ/-*\WL?M(SMPDF,X&JEQ@'$RF4WX,_M=L=&(DZ4D+ MU*P+U&6Z$Z(F=QR)'*DDO%IB/G0M1%M]=C^K/ZD&E0VC7]])E8!78\J7S3/E M+J/M&<+CQ"@;OF=^C2B_/6^<-+F?$??,+P-JS\?2O)<*D[>9=]0[=7)/&QO5 ME?6W!=V?V0;[5OUH!IE5#3)_@$'&V&SDVGJM0%XUSJR+<7;LYU2&5/RI++4$ MHYNA9H<::KE+6&&V/RWSYYETG^P6BRWY;S@VSYP9NVRI:/@MG)"=C)03#K M3SK928]U9UXB?HX]W%$PF$FP3P>6>6>*_4Y&^'$$SN+H(6OR,Z:IT6SQ!.1A M0SME4?;2"4*GP'I=@:XYBZ')!4B.5!GG8+I/81]H)O O''[0]R$<="' M*$F["7[8BY0=&L6;XS.>0>M!O03%[RJPA\3T4IU:'H)_J<=-G:,W*YC+=UCH M(U[^(6_ID'27RK8G75V4<7\23$XFA[@HW!&+MZ@A;]Z!5"5K]V<&P6@ZVE=L M:/DS7C@^JRF'D'<\D68/"[(>8,I;X#=G"G%;QVGV;*MG5[J.6^A_WZ1WU_"W M O6]HE_W"-V"7W??7RWV=4\O0U_WMWN9M2J=9U(/>L:GL)?]GU@T'T2_07,F M!5E;* _@9=#+#K5EGA&K,:\$XG/&O+8A\X!T7%,BW%VN+0\M&1/F&8SVU1_5 M?,U.9I1N?*#Y\NF8O;$X:[5=@].]A?*6[?)HB\]KN*:GTT+/_V6 M1/[16HW=*<7S['HYKJAOZG4HEOP./WP5"]VDZ?74/1 M)F:25/-*C9 SE@E>(.UE@-S11VY9>7MTG8%#"BV4KOE7-W@J)7N2BHPY%G[GJ>N M&0A9L$+Q>>48Y )D!NO[)3/3*32]V HV*OMA-74D064,"_ M)_W)4SQM^.GGYV26%'M=6F.^@3&?ZS%[GWY!'+$'XHCOP9&]#B^>M.UH'G84 M!:2BZ9X(W.8/ _^8:5KT\9%Q46I#I!W%G@6IA 3_MCX*3\=17$-E]Q JQ)J=T;KDSG*R=NH&ZE@CT MM<*%O."N2=TFNBP_]CHGLY&07\V>V1T#X/9R3#H3P:_.L+;WUR15J2A M9V5HY=>M)\J[4>-\^I<:B-M7?VN%JTM4E9%"D__2*F_RUFKO/:#!'GA PUDH M?. !#;;W@(9U'GWR1.&-OR5VXY=Q"+K+=AM4764LCQIB/2*MA4G^Q--_"2EY M.@;X%<$T[/>'!O^ ^X14/0YMCG;2V2UWDV/['C==]%=OR@A0BCRAM.>,3V^A^H.C'#8J[%=L7M;8LQ9R586?4YT_7*8>Y# MN9=P-3Q>I[!(Q$1Y;VVD7M'P'-MNJ$%TO.I(ZP0,(N9D, [&_1,U>+N\,#O+ M>5*WS/<7%Q]XE.C8(I0S@*4_LYVDMMGDZ5;+E:<+FJ24=)E8:W$EF(V>LA.K M=E+;*OH"R5"=[J2=RF(5J=)*FE.'W9JZ4T5:5]5W&VSBNJ;9MI+8VD2RZ@0\]G1,A(+5W( M4_A"Y0E#;5MA2DG3)6+NCLJGY.7#%,MLPH_19KE$26>POK00VE76_C0!_Q06_6 MA__[]-_LSXJXC6@4/N)W#4U;BRU=4M[\?JRLZ!.8JM\[Z=&=N54 G'Z*+'"WZU6T%/P8 MWQ?-G[ 6^%! +Y5U8;\)8)%CQGUMZ=1?P]Z@^0LT'?: [;43J?[L]R:.GUB- MBP>]89VQ\2>] PLMY0['34ZZ'/'?C7D#]=1ACBOR+>R&N>^;!G,;SW9C_TMLR#:WCALSG MPYW;=PW3>\QM#[VVC\U_XF?TW,:Y>G($7T*ZDN^-O##OC7B]R;V#7T4?Y;/F M*!%H&'Q#O589*OWT2>/-$UF\>=_EO:"71,[+ET2NU$LBK_2+(=9;.CX86R]I M]O:R6\.$C3<'#W@ZPL&K;>_$3SV<6GE+OD,;/8[[)6#B^[[:ZU@6G_ZG^8QT MX[$%?2M+HZC%(G[L+S&_D&@WFTQWJ*H?G>1:/TKD\/.C3$LO%Z0]NE MZX=9 [^._>D ;=AEE,,$]K*C:O7<(GX0#OZR:[$+K\.LE$&G1>F//19%;(TM MFK@-U=#]\4+,S<=1@QEWJYZY!LX)D+ZWN[F4\I)2MP)1%ZX[[^W':^&RG2S6 MJY?SMU&%2JCF0 9Z 5ONXR2BT>65.K/:7CSB6*^KC/HBDIN@7GZM+\B:M2RZ MOE^O7*ZQ0395XJR+,QI/S]?+A]/$N>(+N]K=-8DHK%GT:&X"60>43=F2@S'< M-TW[<+NW ^B$E^5QF)?FT&<+L;R'#?'$1;/$I]__@Q-ME8O^G**#%XY\\05P M4]]#_,8E^ON':LAA%18T$(U'J&0:TBW WGN(_6Y=IVY$%_OJ1TV:/0.K98Y; MOSIT7$68FA!GVW M $B;XB'6@#BN ;[C/K:' 0 M7/,?56N\Y.I#[^- #DA]C>^Y0QCF5XB/.)<*^3IH\[9;A?B^/8_[CM,!'0\9 M^C.M_E 3I[U!*18N3W+_C0[=!.$!0Z&XTP&,@Y:FO6#/TCP.W&,@E:SPV&TY8.?SS^J(%6^^4Z'=LF,6*%6:T:C$G>UMB3+I@L7 MW4U5&F:7R0EF6F+=/W5=VPNXF5=+%WS635]$^\#JQ[ MQ\[J9&^#-S+ ]0,^SKWS^BZ[VV/@,[W_-G7F+OQSV=LF'><:Z;D&)\[)/!N& MK4QLMG'LDCZ9OJFWG[B]\CVS=C SC@I%=5+8$1L,^FXP6LK&OEYY?IP?QVL.F0?&;A0*O8%Y4"KHTZJ[BG? M6TUAU&&GM.X1?Z86[DFR6E,\,Z;Y2I6#VWMDWXI5E-">UK?J*2=OXK9U3+4S M_:TL_&GV'"=C9_O GWLO]GG,HA%O[9O'4]@;<$H41F M*1#7)0X[S[!_@L!!H@,6X!MS#V4>?08701YH;P^H"BHM,H[7H<:MNDF[ST27 M+OS^>IO'TL][^^^O:*0V'68O?=--U?K+WY_E>?'-_P)02P$"% ,4 " +5"U)^\:4!9(! M Q$0 $P @ $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+ M 0(4 Q0 ( M4+4E(=07NQ0 "L" + " <,! !? M&UL4$L! A0#% @ "U0M2=BMI (^ 0 :0, !$ M ( !TP8 &1O8U!R;W!S+V-O&UL4$L! A0#% @ "U0M29E< MG",0!@ G"< !, ( !0 @ 'AL+W1H96UE+W1H96UE,2YX M;6Q02P$"% ,4 " +5"U)SCB5]48" !Z"@ #0 @ &! M#@ >&PO&PO=V]R:W-H965T M&UL4$L! A0#% @ "U0M2>M-I>TC P +0T !@ M ( !OA8 'AL+W=O&PO=V]R:W-H965T&UL4$L! M A0#% @ "U0M23Q_B?QE P = X !@ ( !OA\ 'AL M+W=OP.C1X@$ M ,P$ 8 " 5DC !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ "U0M25AA MHX"C 0 K0, !@ ( !1R< 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ "U0M24\^!,NC 0 L0, !D ( !KBX 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ "U0M212C MX<34 0 /@4 !D ( !.S0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "U0M25[0AK^Y @ =0H !D M ( !BCH 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ "U0M25*0=3XH @ L@8 !D ( ! MC4@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ "U0M27'3E$>S @ =0P !D ( !!5( 'AL+W=O&PO XML 37 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 38 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 40 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 113 122 1 false 35 0 false 6 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://scivanta.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets (Unaudited) Sheet http://scivanta.com/role/BalanceSheets Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://scivanta.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Operations (Unaudited) Sheet http://scivanta.com/role/StatementsOfOperations Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Statements of Cash Flows (Unaudited) Sheet http://scivanta.com/role/StatementsOfCashFlows Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Statements of Cash Flows (Parenthetical) Sheet http://scivanta.com/role/StatementsOfCashFlowsParenthetical Statements of Cash Flows (Parenthetical) Statements 6 false false R7.htm 00000007 - Disclosure - Basis of Presentation Sheet http://scivanta.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Amended and Restated SCMS License Agreement Sheet http://scivanta.com/role/AmendedAndRestatedScmsLicenseAgreement Amended and Restated SCMS License Agreement Notes 8 false false R9.htm 00000009 - Disclosure - Related Party Transactions Sheet http://scivanta.com/role/RelatedPartyTransactions Related Party Transactions Notes 9 false false R10.htm 00000010 - Disclosure - Note Payable Sheet http://scivanta.com/role/NotePayable Note Payable Notes 10 false false R11.htm 00000011 - Disclosure - Convertible Debentures Sheet http://scivanta.com/role/ConvertibleDebentures Convertible Debentures Notes 11 false false R12.htm 00000012 - Disclosure - Stock-Based Compensation Sheet http://scivanta.com/role/Stock-basedCompensation Stock-Based Compensation Notes 12 false false R13.htm 00000013 - Disclosure - Net Loss Per Common Share Sheet http://scivanta.com/role/NetLossPerCommonShare Net Loss Per Common Share Notes 13 false false R14.htm 00000014 - Disclosure - Stockholders' Equity Sheet http://scivanta.com/role/StockholdersEquity Stockholders' Equity Notes 14 false false R15.htm 00000015 - Disclosure - Stockholders' Equity (Tables) Sheet http://scivanta.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://scivanta.com/role/StockholdersEquity 15 false false R16.htm 00000016 - Disclosure - Basis of Presentation (Details Narrative) Sheet http://scivanta.com/role/BasisOfPresentationDetailsNarrative Basis of Presentation (Details Narrative) Details http://scivanta.com/role/BasisOfPresentation 16 false false R17.htm 00000017 - Disclosure - Amended and Restated SCMS License Agreement (Details Narrative) Sheet http://scivanta.com/role/AmendedAndRestatedScmsLicenseAgreementDetailsNarrative Amended and Restated SCMS License Agreement (Details Narrative) Details http://scivanta.com/role/AmendedAndRestatedScmsLicenseAgreement 17 false false R18.htm 00000018 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://scivanta.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://scivanta.com/role/RelatedPartyTransactions 18 false false R19.htm 00000019 - Disclosure - Note Payable (Details Narrative) Sheet http://scivanta.com/role/NotePayableDetailsNarrative Note Payable (Details Narrative) Details http://scivanta.com/role/NotePayable 19 false false R20.htm 00000020 - Disclosure - Convertible Debentures (Details Narrative) Sheet http://scivanta.com/role/ConvertibleDebenturesDetailsNarrative Convertible Debentures (Details Narrative) Details http://scivanta.com/role/ConvertibleDebentures 20 false false R21.htm 00000021 - Disclosure - Net Loss Per Common Share (Details Narrative) Sheet http://scivanta.com/role/NetLossPerCommonShareDetailsNarrative Net Loss Per Common Share (Details Narrative) Details http://scivanta.com/role/NetLossPerCommonShare 21 false false R22.htm 00000022 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://scivanta.com/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://scivanta.com/role/StockholdersEquityTables 22 false false R23.htm 00000023 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity (Details) Sheet http://scivanta.com/role/StockholdersEquity-ScheduleOfStockOptionActivityDetails Stockholders' Equity - Schedule of Stock Option Activity (Details) Details 23 false false R24.htm 00000024 - Disclosure - Stockholders' Equity - Schedule of Stock Options Outstanding and Stock Options Exercisable (Details) Sheet http://scivanta.com/role/StockholdersEquity-ScheduleOfStockOptionsOutstandingAndStockOptionsExercisableDetails Stockholders' Equity - Schedule of Stock Options Outstanding and Stock Options Exercisable (Details) Details 24 false false All Reports Book All Reports scvm-20160731.xml scvm-20160731.xsd scvm-20160731_cal.xml scvm-20160731_def.xml scvm-20160731_lab.xml scvm-20160731_pre.xml true true ZIP 42 0001493152-16-013281-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-16-013281-xbrl.zip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end

Stockholders' Equity - Schedule of Stock Option Activity (Details)	9 Months Ended
	Jul. 31, 2016 USD ($) $ / shares shares
Warrant [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Option/Warrants Shares, Outstanding Beginning Balance \| shares	750,000
Stock Option/Warrants Shares, Granted/Issued during the period \| shares	153,846
Stock Option/Warrants Shares, Exercised during the period \| shares
Stock Option/Warrants Shares, Expired during the period \| shares
Stock Option/Warrants Shares, Outstanding Ending Balance \| shares	903,846
Stock Option/Warrants Shares, Exercisable at July 31, 2016 \| shares	673,077
Stock Option/Warrants Shares, Exercisable at October 31, 2015 \| shares	596,154
Weighted Average Exercise Price Per Common Share/Warrants, Outstanding Beginning Balance \| $ / shares	$ 0.12
Weighted Average Exercise Price Per Common Share/Warrants, Granted/Issued during the period \| $ / shares	0.07
Weighted Average Exercise Price Per Common Share/Warrants, Exercised during the period \| $ / shares
Weighted Average Exercise Price Per Common Share/Warrants, Expired during the period \| $ / shares
Weighted Average Exercise Price Per Common Share/Warrants Outstanding Ending Balance \| $ / shares	0.11
Weighted Average Exercise Price Per Common Share, Exercisable at July 31, 2016 \| $ / shares	0.13
Weighted Average Exercise Price Per Common Share, Exercisable at October 31, 2015 \| $ / shares	$ 0.13
Aggregate Intrinsic Value, Outstanding Stock Option/Warrants Beginning balance \| $
Aggregate Intrinsic Value Outstanding Stock Option/Warrants, Ending Balance \| $
Aggregate Intrinsic Value, Stock Option/Warrants, Exercisable at July 31, 2016 \| $
Aggregate Intrinsic Value, Stock Option/Warrants, Exercisable at October 31, 2015 \| $
Stock Option [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Option/Warrants Shares, Outstanding Beginning Balance \| shares	203,332
Stock Option/Warrants Shares, Granted/Issued during the period \| shares
Stock Option/Warrants Shares, Exercised during the period \| shares
Stock Option/Warrants Shares, Expired during the period \| shares	(10,000)
Stock Option/Warrants Shares, Outstanding Ending Balance \| shares	193,332
Stock Option/Warrants Shares, Exercisable at July 31, 2016 \| shares	193,332
Stock Option/Warrants Shares, Exercisable at October 31, 2015 \| shares	203,332
Weighted Average Exercise Price Per Common Share/Warrants, Outstanding Beginning Balance \| $ / shares	$ 1.70
Weighted Average Exercise Price Per Common Share/Warrants, Granted/Issued during the period \| $ / shares
Weighted Average Exercise Price Per Common Share/Warrants, Exercised during the period \| $ / shares
Weighted Average Exercise Price Per Common Share/Warrants, Expired during the period \| $ / shares	0.80
Weighted Average Exercise Price Per Common Share/Warrants Outstanding Ending Balance \| $ / shares	1.74
Weighted Average Exercise Price Per Common Share, Exercisable at July 31, 2016 \| $ / shares	1.74
Weighted Average Exercise Price Per Common Share, Exercisable at October 31, 2015 \| $ / shares	$ 1.70
Aggregate Intrinsic Value, Outstanding Stock Option/Warrants Beginning balance \| $
Aggregate Intrinsic Value Outstanding Stock Option/Warrants, Ending Balance \| $
Aggregate Intrinsic Value, Stock Option/Warrants, Exercisable at July 31, 2016 \| $
Aggregate Intrinsic Value, Stock Option/Warrants, Exercisable at October 31, 2015 \| $